

CITATION REPORT

List of articles citing

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

DOI: 10.1056/nejmoa040938

New England Journal of Medicine, 2004, 350, 2129-39.

Source: <https://exaly.com/paper-pdf/36950185/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2192	Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment. 2010 , 4, 178		12
2191	Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab. 1994 , 20, 373		
2190	Molecular markers help characterize neuroendocrine lung tumors. 1996 , 62, 798-809; discussion 809-10		109
2189	Sun Tzu and the Art of Business Sun Tzu and the Art of Business By McNeilly Mark R., Oxford: Oxford University Press, 1996, 225 pages, hard, cover, \$25.00. 1997 , 11, 129-130		1
2188	Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer's disease: an MRI study. 2003 , 61, 1191-5		87
2187	Receptor tyrosine kinases and inhibitors in lung cancer. 2004 , 4, 589-604		28
2186	[Predicting response to Iressa: unexpected mechanism]. 2004 , 20, 750-1		0
2185	Perspectives on the Use of Tumor Markers. 2004 , 19, 20-21		
2184	Novel oncogenic protein kinase inhibitors for cancer therapy. 2004 , 4, 449-55		26
2183	High sensitivity EndoV mutation scanning through real-time ligase proofreading. 2004 , 32, e148		20
2182	The subsidy of pharmaceuticals in Australia: processes and challenges. 2004 , 28, 194-205		36
2181	Therapy for recurrent malignant glioma in adults. 2004 , 4, 759-82		28
2180	Signaling multiplex of the epidermal growth factor receptor. 2004 , 4, 1145-56		2
2179	Proteomic analysis of cellular signaling. 2004 , 1, 343-54		25
2178	EGFR mutations and sensitivity to gefitinib. <i>New England Journal of Medicine</i> , 2004 , 351, 1260-1; author reply 1260-1	59.2	65
2177	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 26-2004. A 56-year-old woman with cough and a lung nodule. <i>New England Journal of Medicine</i> , 2004 , 351, 809-17	59.2	5
2176	From bench to bedside and back again?. 2004 , 170, 1765, 1767		

2175	The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy. 2004 , 1, 2-3	15
2174	Analysis of FDA Approved Anticancer Drugs Reveals the Future of Cancer Therapy. 2004 , 3, 1033-1040	65
2173	Cancer. A bull's eye for targeted lung cancer therapy. 2004 , 304, 1458-61	74
2172	Oncogenic mutations of PIK3CA in human cancers. 2004 , 3, 1221-4	384
2171	New treatment options for colorectal cancer. <i>New England Journal of Medicine</i> , 2004 , 351, 391-2	59.2 33
2170	Cancer drug development: for populations or for individuals?. 2004 , 22, 3441-2	1
2169	Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. 2004 , 10, 8351-6	58
2168	Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. 2004 , 64, 6385-9	158
2167	Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. 2004 , 64, 8816-20	404
2166	The science of recruiting minority populations to screening trials. 2004 , 1, 341-2	7
2165	Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. 2004 , 10, 7311-7	61
2164	Twenty-five years of treating advanced NSCLC: what have we achieved?. 2004 , 15 Suppl 4, iv81-3	11
2163	Assessing prognosis in non-small-cell lung cancer: avenues to a more complete picture?. 2004 , 22, 3209-11	4
2162	Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. 2004 , 10, 7764-74	93
2161	Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents. 2004 , 96, 977-8	53
2160	An agenda for clinical trials: clinical trials in the genomic era. 2004 , 1, 468-70	16
2159	Clinical pharmacology and determinates of response to gefitinib in non-small cell lung cancer. 2004 , 10, 169-175	
2158	Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. 2004 , 96, 1133-41	333

2157	Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study. 2004 , 10, 7112-20	70
2156	Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer. 2004 , 10, 8613-9	17
2155	High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. 2004 , 10, 8195-203	458
2154	Molecular prognostication for soft tissue sarcomas: are we ready yet?. 2004 , 22, 4031-4	29
2153	Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. 2004 , 10, 7547-54	81
2152	Pharmacogenomics and stomach cancer. 2004 , 5, 627-41	6
2151	The miracle of Iressa. 2004 , 9, 245-6	10
2150	Molecularly targeted therapy: have the floodgates opened?. 2004 , 9, 357-60	43
2149	Identification and validation of cell surface antigens for antibody targeting in oncology. 2004 , 11, 659-87	91
2148	Evaluating the efficiency of targeted designs for randomized clinical trials. 2004 , 10, 6759-63	265
2147	Racial disparity of epidermal growth factor receptor expression in prostate cancer. 2004 , 22, 4725-9	77
2146	Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). 2004 , 13, 3029-43	139
2145	c-kit expression in adenocarcinomas of the lung. 2004 , 25, 235-42	26
2144	Inhibition of mutant EGF receptors by gefitinib: targeting an Achilles' heel of lung cancer. 2004 , 3, 1496-7	11
2143	Imatinib: Paradigm or Anomaly?. 2004 , 3, 831-833	11
2142	Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. 2004 , 10, 8594-602	131
2141	Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. 2004 , 10, 6522-7	71
2140	Aligning the stakeholders. 2004 , 5, 605-7	1

2139	The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer. 2004 , 1, 27-34	4
2138	Identification of Gefitinib Target of NSCLC EGFR Gene Mutation Expected to Shift Focus of Drug Development. 2004 , 26, 8-9	
2137	Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. 2004 , 22, 4442-5	200
2136	A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. 2004 , 10, 7812-9	94
2135	Gefitinib induces apoptosis in the EGFR L858R non-small-cell lung cancer cell line H3255. 2004 , 64, 7241-4	316
2134	Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. 2004 , 5, 1621-33	48
2133	Therapeutic targets for antimetastatic therapy. 2004 , 8, 527-36	22
2132	Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. 2004 , 91, 2048-55	58
2131	Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. 2004 , 91, 1301-7	43
2130	EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. 2004 , 101, 13306-11	3659
2129	Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management. 2004 , 91 Suppl 2, S1-2	15
2128	Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. 2004 , 34, 901-15	36
2127	Targeting protein kinases in cancer therapy: a success?. 2004 , 4, 1113-24	41
2126	Targeting targeted therapy. <i>New England Journal of Medicine</i> , 2004 , 350, 2191-3	59.2 119
2125	Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?. 2004 , 96, 1117-9	34
2124	Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. 2004 , 64, 9101-4	105
2123	Cetuximab (Erbix) -- an emerging targeted therapy for epidermal growth factor receptor-expressing tumours. 2004 , 58, 970-6	27
2122	A molecular chink in the lung cancer armour. 2004 , 9, 426-7	

2121	What are the reasons for negative phase III trials of molecular-target-based drugs?. 2004 , 95, 772-6	12
2120	Kinase inhibitors in cancer therapy. 2004 , 2, 177-93	22
2119	Imatinib mesylate for melanoma: will a new target be revealed?. 2004 , 123, xi-xiii	7
2118	The impact of systems approaches on biological problems in drug discovery. 2004 , 22, 1215-7	187
2117	Will tomorrow's medicines work for everyone?. 2004 , 36, S34-42	112
2116	Selecting the right patient for tumor therapy. 2004 , 10, 577-8	21
2115	Cancer genes and the pathways they control. 2004 , 10, 789-99	3175
2114	Creating incentives for genomic research to improve targeting of therapies. 2004 , 10, 1289-91	13
2113	No longer in the dark. 2004 , 4, 415-416	2
2112	Insulin-like growth factors and neoplasia. 2004 , 4, 505-18	1286
2111	Switching on kinases: oncogenic activation of BRAF and the PDGFR family. 2004 , 4, 718-27	142
2110	Gefitinib--a novel targeted approach to treating cancer. 2004 , 4, 956-65	283
2109	Targeted lung cancer therapies. 2004 , 3, 547-8	5
2108	Pharmacogenomics: bench to bedside. 2004 , 3, 739-48	220
2107	Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. 2004 , 3, 763-9	159
2106	Strategies to overcome resistance to targeted protein kinase inhibitors. 2004 , 3, 1001-10	276
2105	Development of TGF-beta signalling inhibitors for cancer therapy. 2004 , 3, 1011-22	452
2104	Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. 2004 , 5, 669-76	300

2103	Pharmacogenetics: ethical problems and solutions. 2004 , 5, 676-80	28
2102	Pharmacogenetics and drug development: the path to safer and more effective drugs. 2004 , 5, 645-56	233
2101	RNAi and HTS: exploring cancer by systematic loss-of-function. 2004 , 23, 8392-400	49
2100	DNA-microarray analysis of brain cancer: molecular classification for therapy. 2004 , 5, 782-92	166
2099	Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer. 2004 , 91, 430-3	16
2098	S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas. 2004 , 91, 1515-24	39
2097	Astronomy: where are Procyon's quakes?. 2004 , 430, 29-30	10
2096	Cancer: understanding the target. 2004 , 430, 30	12
2095	Athletics: momentous sprint at the 2156 Olympics?. 2004 , 431, 525	54
2094	Lung cancer: intragenic ERBB2 kinase mutations in tumours. 2004 , 431, 525-6	655
2093	Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer. 2004 , 5, 331-2	
2092	2004 highlights from: 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, June 2004. 2004 , 6, 11-6	
2091	Impact of genetic polymorphisms in DNA repair enzymes on drug resistance in lung cancer. 2004 , 6, 79-82	7
2090	Emerging role of erlotinib (OSI-774) in non-small-cell lung cancer. 2004 , 6 Suppl 1, S6	
2089	Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow. 2004 , 5, 411-5	68
2088	Molecular approach to breast cancer treatment. 2004 , 31, 6-13	59
2087	Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. 2004 , 31, 27-31	11
2086	Using germ-line genetic variation to investigate and treat cancer. 2004 , 9, 610-8	9

2085	The story of gefitinib, an EGFR kinase that works in lung cancer. 2004 , 9, 587	4
2084	Bioinformatics and cancer target discovery. 2004 , 9, 795-802	35
2083	Role of pathologists in the molecular targeted therapy of cancer. 2004 , 54, S342-S348	
2082	Proteomic analysis of human breast cancer tissue with laser-capture microdissection and reverse-phase protein microarrays. 2004 , 5, 385-92	55
2081	Epidermal growth factor receptor as a target to improve treatment of lung cancer. 2004 , 5, 340-52	7
2080	Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. 2004 , 6, 123-8	124
2079	Therapeutic advances in second-line treatment of advanced non-small-cell lung cancer. 2004 , 6, 154-61	11
2078	Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. 2004 , 6 Suppl 1, S7-S19	29
2077	Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. 2004 , 6 Suppl 1, S24-9	38
2076	Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors. 2004 , 6 Suppl 1, S30-4	15
2075	Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs. 2004 , 6 Suppl 1, S35-42	8
2074	Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma. 2004 , 6 Suppl 1, S43-7	3
2073	Use of proteasome inhibition in the treatment of lung cancer. 2004 , 6 Suppl 2, S89-96	18
2072	Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. 2004 , 500, 267-80	58
2071	Chemotherapy in hormone refractory prostate cancer: where do we stand?. 2004 , 46, 709-11	5
2070	Apoptosis pathway-targeted drugs--from the bench to the clinic. 2004 , 1705, 53-66	29
2069	Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?. 2004 , 5, 525-31	82
2068	Focus on bladder cancer. 2004 , 6, 111-6	221

2067	c-Src and cooperating partners in human cancer. 2004 , 6, 209-14	481
2066	The convergence of cancer prevention and therapy in early-phase clinical drug development. 2004 , 6, 321-6	41
2065	Somatic alterations in the human cancer genome. 2004 , 6, 433-8	128
2064	Targeting cell cycle and apoptosis for the treatment of human malignancies. 2004 , 16, 670-8	87
2063	Inhibition of akt/protein kinase B signaling by naltrindole in small cell lung cancer cells. 2004 , 64, 8723-30	35
2062	Palliative Systemtherapie beim metastasierten Ösophaguskarzinom. 2004 , 10, 1202-1214	1
2061	The epidermal growth factor receptor as a target for gastrointestinal cancer therapy. 2004 , 5, 393-403	11
2060	Lung adenocarcinoma and human papillomavirus infection. 2004 , 101, 1428-36	52
2059	Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. 2004 , 101, 1632-8	68
2058	Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly. 2004 , 101, 1733-44	7
2057	Role of pharmacogenomics in drug development. 2004 , 62, 86-96	6
2056	Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases. 2004 , 8, 432-41	39
2055	New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. 2004 , 6, 204-10	47
2054	Evolution de la stratégie thérapeutique en situation métastatique du cancer bronchique non ^ petites cellules. 2004 , 3, 9-10	
2053	Epidermal growth factor receptor inhibition strategies in oncology. 2004 , 11, 689-708	275
2052	Targeted Therapies for Cancer 2004. 2004 , 122, 598-609	220
2051	Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. 2004 , 64, 9093-100	132
2050	An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. 2004 , 64, 9139-43	224

2049	Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. 2004 , 22, 3238-47	922
2048	Carcinomes plfomorphes : un dilemme diagnostic. 2004 , 24, 88-90	
2047	Adhocarcinomes pulmonaires : un challenge pour la dtection prcoce. 2004 , 24, 85-88	
2046	[Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting]. 2004 , 21, 881-5	0
2045	[Prediction of response to tyrosine kinase epithelial cell growth factor receptor inhibitors: a major breakthrough in the treatment of non-small-cell lung cancer]. 2004 , 60, 252-3	
2044	Unraveling lung cancer biology by animal models and gene expression profiling. 2004 , 1, 25-30	
2043	Biomarkers in cancer management: a crucial bridge toward personalized medicine. 2004 , 1, 305-311	1
2042	Targeted therapies for cancer [from tamoxifen to gefitinib (Iressa)] 2004 , 1, 411-416	2
2041	Network-targeted combination therapy: a new concept in cancer treatment. 2004 , 1, 425-433	12
2040	The combination of cytotoxic and molecularly targeted therapies [can it be done?]. 2004 , 1, 445-454	5
2039	Population genetics for target identification. 2004 , 1, 69-74	10
2038	Program to improve cognitive functioning in patients with schizophrenia: reflections. 2004 , 72, 75-7	4
2037	Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer. 2004 , 64, 2475-92	19
2036	Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. 2004 , 6 Suppl 1, S20-3	73
2035	Bronchoalveolar carcinoma: current treatment and future trends. 2004 , 6 Suppl 2, S75-9	3
2034	Translation research: from accurate diagnosis to appropriate treatment. 2004 , 2, 35	25
2033	Biotechs Continue their Assault on Cancer. 2004 , 2, 23-26	
2032	Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. 2004 , 64, 8919-23	1059

2031	[The pathologist and EGFR in 2004: I like you, nor do it]. 2004 , 24, 416-26		1
2030	Somatic mutations of EGFR in colorectal cancers and glioblastomas. <i>New England Journal of Medicine</i> , 2004 , 351, 2883	59.2	255
2029	Méthodologie d'évaluation des thérapies ciblées dans les essais cliniques. perspectives d'avenir. 2004 , 60, 72-78		
2028	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. <i>New England Journal of Medicine</i> , 2004 , 351, 337-45	59.2	4112
2027	Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling. 2004 , 7, 245-55		28
2026	Chemotherapy for advanced lung cancer. 2004 , 40, 2345-8		11
2025	Pharmacogenomics in cancer therapy: is host genome variability important?. 2004 , 25, 457-64		30
2024	Mutations and addiction to EGFR: the Achilles 'heel' of lung cancers?. 2004 , 10, 481-6		251
2023	Beyond fast track for drug approvals. <i>New England Journal of Medicine</i> , 2004 , 351, 501-5	59.2	41
2022	Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. 2004 , 305, 1163-7		1400
2021	Technology platforms for pharmacogenomic diagnostic assays. 2004 , 3, 749-61		81
2020	Biomedical marker molecules for cancer [current status and perspectives]. 2004 , 3, 228-237		6
2019	EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. 2004 , 304, 1497-500		7937
2018	Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. 2004 , 72, 257-66		138
2017	Challenges in breast cancer clinical trial design in the postgenomic era. 2004 , 16, 536-41		13
2016	Molecular pathology in oncology--the AstraZeneca perspective. 2004 , 5, 1167-73		4
2015	Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE). 2004 , 14, 295-300		16
2014	Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors. 2004 , 16 Suppl 4, 55-8		4

2013	Emerging strategies and applications of pharmacogenomics. 2004 , 1, 444-55	6
2012	Aberrant methylation: common in thymic carcinomas, rare in thymomas. 2005 , 14, 1621	4
2011	Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. 2005 , 65, 3003-10	98
2010	Targets and Approaches for Cancer Drug Discovery. 2005 , 1343-1373	
2009	Somatic mutations in human cancer: insights from resequencing the protein kinase gene family. 2005 , 70, 43-9	21
2008	Use of recombinant factor VIIa for life-threatening bleeding in a patient with severe necrotizing pancreatitis. 2005 , 31, 292-4	1
2007	Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. 2005 , 70, 139-48	145
2006	Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials. 2005 , 17, 123-9	7
2005	Os nveis sfcos de Cyfra 21-1 sã factores preditivos da sobrevida dos doentes com carcinoma pulmonar de nã pequenas clulas submetidos a gefitinib como terapũtica de terceira linha.. 2005 , 11, 413-415	
2004	Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. 2005 , 128, 3975-84	88
2003	Association between epidermal growth factor receptor mutation and improved survival in never-smokers with primary adenocarcinoma of the lung. 2005 , 127, 2292	2
2002	Biologie des cancers bronchiques. 2005 , 2, 1-16	
2001	Emerging trends in combinations of gefitinib and cytotoxic agents: new opportunities. 2005 , 28, 467-70	
2000	Lung cancer: genetics of risk and advances in chemoprevention. 2005 , 11, 265-71	24
1999	Granular cell tumor of the pancreas. 2005 , 31, 296-8	8
1998	Program for the Assessment of Clinical Cancer Tests (PACCT): assisting the development of tailored cancer therapy. 2005 , 2, 363-369	1
1997	Dissecting cancer pathways and vulnerabilities with RNAi. 2005 , 70, 435-44	27
1996	Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. 2005 , 70, 419-26	91

1995	Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. 2005 , 70, 73-81	34
1994	EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm. 2005 , 12, 47-52	2
1993	Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung. 2005 , 16, 739-42	2
1992	Treatment of non-small cell lung cancer and targeted therapies: where are we?. 2005 , 17, 114-7	1
1991	Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. 2005 , 17, 118-22	54
1990	Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. 2005 , 28, 340-4	28
1989	Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. 2005 , 28, 570-5	73
1988	The treatment of advanced non-small cell lung cancer. 2005 , 11, 287-91	41
1987	Massive biliary pleural effusion induced by pancreatic-thoracic fistula. 2005 , 31, 295-6	
1986	Acute pancreatitis associated with irbesartan therapy. 2005 , 31, 294-5	9
1985	Pancreatic carcinosarcoma with unique triphasic histological pattern. 2005 , 31, 291-2	17
1984	Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics. 2005 , 70, 499-515	24
1983	Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): potential basis for a new therapeutic approach. 2005 , 29, 485-9	38
1982	"Lineage addiction" in human cancer: lessons from integrated genomics. 2005 , 70, 25-34	24
1981	Screens using RNAi and cDNA expression as surrogates for genetics in mammalian tissue culture cells. 2005 , 70, 449-59	20
1980	EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. 2005 , 29, 633-9	206
1979	Targeted lung cancer therapy: what have we learned from gefitinib?. 2005 , 2, 1-2	3
1978	Genomics-based prognosis and therapeutic prediction in breast cancer. 2005 , 3, 291-300	47

1977	Pharmacogenetics and the future of medicine. 2005 ,	
1976	Development of Precise Pharmacodiagnostic (PharmDx) Tests for Molecular Targeted Therapies. 2005 , 38, 209-216	1
1975	EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. 2005 , 65, 7568-72	227
1974	Sputum eosinophils and bronchodilator reversibility: COPD or asthma?. 2005 , 127, 2292-3	1
1973	Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: a prospective phase II study. 2005 , 17, 679-84	18
1972	Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. 2005 , 128, 317-21	101
1971	Targeting COX-2/PG-E2 with a COX-2 inhibitor in combination with chemotherapy for non-small cell lung cancer: are we ready for phase III?. 2005 , 11, 201-3	1
1970	Prognóstico do cancro do pulmão: Novos factores biológicos e moleculares. 2005 , 11, S113-S122	
1969	Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. 2005 , 28, 481-6	25
1968	New approaches to drug development in pediatric oncology. 2005 , 11, 324-30	16
1967	New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004. 2005 , 16, 211-21	26
1966	Chemotherapy strategies in the treatment of small cell lung cancer. 2005 , 16, 361-72	13
1965	Association of hepatitis a and acute pancreatitis presenting as acute abdomen. 2005 , 31, 298-9	4
1964	Epidermal growth factor receptor gene is highly conserved in pancreatic cancer cells. 2005 , 31, 299	4
1963	ABC transporters in the balance: is there a role in multidrug resistance?. 2005 , 33, 241-5	80
1962	After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. 2005 , 105, 22-30	50
1961	Pharmacogenomics of Cholestatic Liver Disease. 2005 , 407-416	
1960	What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer?. 2005 , 2, 290-1	

1959	Characterization of lipophilicity and antiproliferative activity of E-2-arylmethylene-1-tetralones and their heteroanalogues. 2005 , 819, 283-91	23
1958	Activation patterns of epidermal growth factor-receptor signaling in glioblastoma multiforme: in regard to Chakravarti et al. (Int J Radiat Oncol Biol Phys 2005;62:318-327). 2005 , 62, 1253; author reply 1253	
1957	Facile synthesis of 7-amino anilinoquinazolines via direct amination of the quinazoline core. 2005 , 46, 7381-7384	2
1956	Targeting ligand cleavage to inhibit the ErbB pathway in cancer. 2005 , 1059, 56-60	3
1955	Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status. 2005 , 23, 73-7	32
1954	Evolving molecular-based targeted therapy for cancer: an exciting field. 2005 , 31, 299-305	
1953	FLT3 tyrosine kinase inhibitors. 2005 , 82, 100-7	62
1952	Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective. 2005 , 19, 385-93	37
1951	Therapeutic approaches in arterial thrombosis. 2005 , 3, 1577-89	63
1950	Trial design for testing new therapies in ovarian cancer. 2005 , 15 Suppl 3, 258-65	4
1949	Standard treatment in advanced ovarian cancer in 2005: the state of the art. 2005 , 15 Suppl 3, 212-20	53
1948	Diagnostic challenges in pathology. 2005 , 15, 403-405	
1947	CpG Island methylation patterns in various histotypes of endometrial cancer. 2005 , 15, 405-405	
1946	Novel strategies for the management of uterine malignant mixed mullerian tumors. 2005 , 15, 405-405	0
1945	What is the correct management of stage i UPSC?. 2005 , 15, 405-406	2
1944	Advances in the management of advanced and recurrent uterine papillary serous carcinoma. 2005 , 15, 406-406	1
1943	Is lymphadenectomy required for all patients with endometrial cancer?. 2005 , 15, 406-407	2
1942	Laparoscopically assisted surgical staging for endometrial cancer. 2005 , 15, 407-407	12

1941	Updates in chemotherapy in the treatment of advanced and recurrent endometrial cancer. 2005 , 15, 407-408	1
1940	The role of radiation treatment in intermediate risk endometrial cancer-pro. 2005 , 15, 408-409	
1939	Role of radiation treatment in intermediate risk endometrial cancer-con. 2005 , 15, 409-409	1
1938	Future challenges in clinical and translational research for endometrial cancer. 2005 , 15, 398-399	4
1937	Tyrosine kinase inhibitors in endometrial cancer. 2005 , 15, 409-411	15
1936	Novel biologic therapies for the treatment of endometrial cancer. 2005 , 15, 411-411	17
1935	Role of gene expression profiling in distinguishing biologically and clinically distinct subclasses of endometrial carcinoma. 2005 , 15, 403-403	
1934	Early molecular changes in endometrial cancer. 2005 , 15, 399-400	4
1933	Loss of cables is associated with development of endometrial hyperplasia and cancer. 2005 , 15, 400-400	
1932	Endometrial cancer in women with HNPCC. 2005 , 15, 400-401	7
1931	Atypical endometrial hyperplasia: A tough call. 2005 , 15, 401-401	7
1930	Controversies in the management of atypical hyperplasia: Conservative management vs. simple hysterectomy. 2005 , 15, 401-402	
1929	Predictors of poor prognosis in endometrial cancer. 2005 , 15, 402-402	
1928	MSI in endometrial cancer: Prevalence and clinical applications. 2005 , 15, 402-403	2
1927	Genetics of drug resistance. 2005 , 46 Suppl 10, 33-8	19
1926	Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations. 2005 , 31, 384-94	35
1925	Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy?. 2005 , 47, 560-4	45
1924	Throwing new light on lung cancer pathogenesis: updates on three recent topics. 2005 , 96, 63-8	19

1923	Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. 2005 , 21, 321-39	39
1922	CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy. 2005 , 92, 13-4	28
1921	Lack of clinical efficacy of imatinib in metastatic melanoma. 2005 , 92, 1398-405	224
1920	Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib. 2005 , 92, 1690-5	26
1919	Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). 2005 , 92, 1711-9	122
1918	Role of novel targeted therapies in the clinic. 2005 , 92 Suppl 1, S21-7	11
1917	Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma. 2005 , 92, 2266-77	48
1916	Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients. 2005 , 93, 23-8	45
1915	Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. 2005 , 93, 504-9	67
1914	Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. 2005 , 93, 719-29	115
1913	HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. 2005 , 93, 1334-40	70
1912	A small molecule-kinase interaction map for clinical kinase inhibitors. 2005 , 23, 329-36	1569
1911	Response to Moleculekinase interaction map. 2005 , 23, 1346-1348	0
1910	Plant transgenic science knowledge. 2005 , 23, 1348-9	9
1909	Priorities and standards in pharmacogenetic research. 2005 , 37, 671-81	116
1908	Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. 2005 , 37, 1315-6	405
1907	Timeline: Chemotherapy and the war on cancer. 2005 , 5, 65-72	1259
1906	ERBB receptors and cancer: the complexity of targeted inhibitors. 2005 , 5, 341-54	2593

1905	Killing time for cancer cells. 2005 , 5, 573-80	77
1904	The concept of synthetic lethality in the context of anticancer therapy. 2005 , 5, 689-98	1061
1903	Biomarkers in cancer staging, prognosis and treatment selection. 2005 , 5, 845-56	1278
1902	Oncogenic PI3K deregulates transcription and translation. 2005 , 5, 921-9	622
1901	Erlotinib hydrochloride. 2005 , 4, 13-4	142
1900	Cancer drug discovery through collaboration. 2005 , 4, 375-80	24
1899	News Analysis. 2005 , 4, 874-875	
1898	Exploiting the PI3K/AKT pathway for cancer drug discovery. 2005 , 4, 988-1004	1618
1897	Carcinogenesis, cancer therapy and chemoprevention. 2005 , 12, 592-602	69
1896	Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. 2005 , 15, 212-7	51
1895	Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway. 2005 , 24, 616-26	50
1894	RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. 2005 , 24, 829-37	38
1893	Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas. 2005 , 24, 141-7	96
1892	Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). 2005 , 24, 1412-22	98
1891	Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. 2005 , 24, 1847-59	67
1890	TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. 2005 , 24, 3002-10	101
1889	The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. 2005 , 24, 4433-41	110
1888	Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. 2005 , 24, 6646-56	315

1887	Predominance of high-grade pathway in breast cancer development of Middle East women. 2005 , 18, 891-7	51
1886	Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. 2005 , 18, 1350-6	125
1885	EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. 2005 , 18, 1027-33	252
1884	Interaction maps for kinase inhibitors. 2005 , 23, 308-9	13
1883	Adding diversity to plant transformation. 2005 , 23, 309-10	15
1882	Targeted therapies for non-small cell lung cancer. 2005 , 59, 1055-62	13
1881	Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities. 2005 , 34, 449-59	19
1880	ERBB2 kinase domain mutation in a gastric cancer metastasis. 2005 , 113, 683-7	17
1879	Targeted therapies in breast cancer. 2005 , 11 Suppl 1, S30-5	16
1878	Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. 2005 , 7, 301-11	794
1877	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. 2005 , 7, 387-97	2353
1876	Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. 2005 , 7, 575-89	413
1875	Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. 2005 , 8, 227-39	204
1874	Combinatorial biomarkers: From early toxicology assays to patient population profiling. 2005 , 10, 781-8	29
1873	2004 Highlights From: 29th European Society of Medical Oncology Congress Vienna, Austria October 29 through November 2, 2004. 2005 , 6, 272-275	
1872	2005 Highlights From: 96th Annual Meeting of AACR Anaheim, CA, April 2005 41st Annual Meeting of ASCO Orlando, FL, May 2005. 2005 , 6, 333-337	
1871	Role of epidermal growth factor receptor mutations in predicting sensitivity or resistance to targeted agents in non-small-cell lung cancer. 2005 , 6, 338-9	
1870	Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer. 2005 , 7, 163-5	3

1869	Biologic staging of non-small-cell lung cancer: prospect or proposal?. 2005 , 6, 225-6	
1868	Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial. 2005 , 6, 214-6	1
1867	Epidemiology of lung cancer. 2005 , 40, 83-9	17
1866	Redefining bronchioloalveolar carcinoma. 2005 , 32, 329-35	20
1865	Current management of advanced non-small cell lung cancer: targeted therapy. 2005 , 32, 315-28	39
1864	Adjuvant chemotherapy in early-stage non-small cell lung cancer. 2005 , 32, 279-83	10
1863	Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. 2005 , 32, S35-41	23
1862	The role of cetuximab in the therapy of previously treated advanced colorectal cancer. 2005 , 32, S55-8	6
1861	Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. 2005 , 32, S59-62	27
1860	Other compounds and targets in non-small cell lung cancer. 2005 , 32, S30-6	5
1859	An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer. 2005 , 32, S3-8	79
1858	Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations. 2005 , 32, S9-15	69
1857	[Targeted biotherapies in digestive oncology: a new era in therapeutic management?]. 2005 , 29, 495-500	1
1856	The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. 2005 , 129, 1010-7	15
1855	Molecular epidemiology of cancer. 2005 , 55, 45-54; quiz 57	73
1854	Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial. 2005 , 7, 127-32	29
1853	Targeting multiple signal transduction pathways in lung cancer. 2005 , 7 Suppl 1, S39-44	18
1852	Recent advances and future perspectives in the management of lung cancer. 2005 , 42, 540-610	1

1851	A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. 2005 , 99, 50-7	61
1850	Immunobiotherapy directed against mutated and aberrantly expressed gene products in pancreas cancer. 2005 , 94, 1069-77	4
1849	Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 2005 , 205, 355-63	26
1848	Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate. 2005 , 27, 1022-7	36
1847	Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. 2005 , 113, 510-1	81
1846	Expression patterns of potential therapeutic targets in prostate cancer. 2005 , 113, 619-28	130
1845	Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. 2005 , 116, 36-44	119
1844	Absence of the ERBB2 kinase domain mutation in lung adenocarcinomas in Korean patients. 2005 , 116, 652-3	5
1843	Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. 2005 , 117, 883-8	133
1842	Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. 2005 , 103, 1265-73	107
1841	Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. 2005 , 103, 1670-5	97
1840	High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. 2005 , 103, 2344-8	188
1839	Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma. 2005 , 103, 2566-74	67
1838	Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. 2005 , 103, 2435-46	69
1837	EGFR gene copy number heterogeneity in fine-needle aspiration cytology from breast carcinomas determined by chromogenic in situ hybridization. 2005 , 33, 228-32	11
1836	Protein-interaction mapping in search of effective drug targets. 2005 , 27, 958-69	14
1835	The molecular biology of esophageal adenocarcinoma. 2005 , 92, 169-90	99
1834	Clinical relevance of ion channels for diagnosis and therapy of cancer. 2005 , 205, 175-84	78

1833	Chronic myeloid leukemia: a model for oncology. 2005 , 84, 487-97	43
1832	Translational studies for target-based drugs. 2005 , 56 Suppl 1, 90-3	11
1831	[Basics of molecular diagnostics and therapy of malignant tumors]. 2005 , 46, 835-6, 838-42, 844-6	0
1830	Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors. 2005 , 83, 976-83	25
1829	Genetic analysis of the kinome and phosphatome in cancer. 2005 , 62, 2092-9	47
1828	[EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer]. 2005 , 100, 785-93	2
1827	Blockade of epidermal growth factor receptor (EGFR) activity. 2005 , 53, 179-92	17
1826	Predicting drug response and toxicity based on gene polymorphisms. 2005 , 54, 171-96	86
1825	Molecular targets for altering radiosensitivity: lessons from Ras as a pre-clinical and clinical model. 2005 , 55, 103-16	18
1824	Prognosefaktoren beim Lungenkarzinom. 2005 , 2, 77-82	
1823	Perspektiven der Targeted therapy 2005 , 2, 268-275	
1822	Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa). 2005 , 13, 70-2	21
1821	Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. 2005 , 446, 483-8	89
1820	Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. 2005 , 131, 649-52	90
1819	Antibody-based targeted therapy for gastric cancer. 2005 , 8, 206-8	7
1818	Cancer pharmacogenomics: international trends. 2005 , 10, 5-13	20
1817	Pharmacogénétique et pharmacogénomie, quelle est la différence?. 2005 , 7, 4-5	
1816	Apports de la pharmacogénomique et de la pharmacogénétique dans les cancers digestifs. 2005 , 7, 619-625	

1815 Tyrosinkinaseinhibitoren und monoklonale Antikörper. **2005**, 11, 16-20

1814 Wirksamkeit von Cetuximab und Irinotecan beim metastasierten kolorektalen Karzinom □
EGF-Rezeptor-negativ. **2005**, 11, 783-784

1813 Molekulare Diagnostik bei nicht-hämatologischen malignen Erkrankungen. **2005**, 11, 873-888

1812 Einsatz von Erlotinib: prognostische und prädiktive Faktoren beim nichtkleinzelligen
Lungenkarzinom. **2005**, 11, 36-39

1811 Erlotinib in der Second-Line-Therapie nichtkleinzelliger Lungenkarzinome. **2005**, 11, 29-35

3

1810 Genomics of lung cancer may change diagnosis, prognosis and therapy. **2005**, 11, 5-10

15

1809 Clinical review of Iressa for the treatment of NSCLC. **2005**, 2, 829-833

1808 Gefitinib therapy for non-small cell lung cancer. **2005**, 6, 75-81

19

1807 Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic
malignancies. **2005**, 6, 103-14

17

1806 Targeted therapies for gynecologic malignancies. **2005**, 6, 121-32

2

1805 Targeted molecular therapy of malignant gliomas. **2005**, 5, 186-97

44

1804 Epidermal growth factor receptor expression in renal cell carcinoma: rationale for therapy with
sidling blockade. **2005**, 7, 87-9

1

1803 Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. **2005**, 7, 116-22

4

1802 Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor.
2005, 7, 123-8

3

1801 Unique issues in the development of "targeted" antineoplastic pharmaceutical agents. **2005**, 7, 235-6

1

1800 Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. **2005**, 7, 241-7

21

1799 Angiogenesis and prostate cancer: important laboratory and clinical findings. **2005**, 7, 215-9

14

1798 A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the
Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
2005, 23, 147-55

31

1797	HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. 2005 , 74, 77-86	60
1796	Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches. 2005 , 75, 267-72	39
1795	Molecular biology of medulloblastoma: will it ever make a difference to clinical management?. 2005 , 75, 273-8	26
1794	Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. 2005 , 92, 1-9	29
1793	EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients. 2005 , 22, 1757-61	17
1792	'A little bitty spot and I'm a big man': patients' perspectives on refusing diagnosis or treatment for lung cancer. 2005 , 14, 636-46	63
1791	Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivasular therapy of human prostate cancer in the prostate of nude mice. 2005 , 65, 203-15	33
1790	Targeted therapy: for kids, too. 2005 , 45, 623-34	2
1789	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development. 2005 , 10, 2611-7	18
1788	Phase I study of vinorelbine plus gemcitabine as third-line chemotherapy for refractory non-small cell lung cancer. 2005 , 14, 689	
1787	CpG ISLAND METHYLATION PATTERNS IN VARIOUS HISTOTYPES OF ENDOMETRIAL CANCER: 0011. 2005 , 15, 405.1-405	
1786	TYROSINE KINASE INHIBITORS IN ENDOMETRIAL CANCER: 0020. 2005 , 15, 409.2-411	
1785	DIAGNOSTIC CHALLENGES IN PATHOLOGY: 0010. 2005 , 15, 403.2-405	
1784	EARLY MOLECULAR CHANGES IN ENDOMETRIAL CANCER: 0001. 2005 , 15, 399-400	4
1783	ENDOMETRIAL CANCER IN WOMEN WITH HNPCC: 0003. 2005 , 15, 400.2-401	
1782	ROLE OF RADIATION TREATMENT IN INTERMEDIATE RISK ENDOMETRIAL CANCER: 0019. 2005 , 15, 409.1-409	
1781	Complexity of cancer as a genetic disease. 2005 ,	
1780	Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. 2005 , 39, S565-8	32

1779	Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer. 2005 , 128, 308-16	18
1778	An Epidermal Growth Factor Receptor Intron 1 Polymorphism in Healthy Women in Poland. 2005 , 20, 184-188	3
1777	ErbB family of receptors include 4 different receptors, each of which, with the exception of ErbB 2, has a number of ligands. 2005 , 6, 241-2	
1776	The era of ErbB-receptor-targeted therapies: advances toward personalized medicine. 2005 , 2, 301-315	3
1775	Translational Research in Radiation Oncology of Lung Cancer. 2005 , 481-493	
1774	Molecular Targeted Therapy for Thyroid Cancer. 2005 , 20, 105	1
1773	A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. 2005 , 16, 1811-6	109
1772	A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. 2005 , 2, e312	84
1771	Targeted therapies for esophageal cancer. 2005 , 10, 590-601	114
1770	Receptor tyrosine kinases as targets for anticancer therapeutics. 2005 , 12, 1773-81	13
1769	Practical management of patients with non-small-cell lung cancer treated with gefitinib. 2005 , 23, 165-74	150
1768	Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. 2005 , 65, 1459-70	249
1767	KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. 2005 , 2, e17	1160
1766	Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. 2005 , 16, 1081-6	189
1765	Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. 2005 , 23, 3288-93	60
1764	Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. 2005 , 65, 7525-9	130
1763	Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors. 2005 , 11, 5668-70	24
1762	Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. 2005 , 4, 650-8	100

1761	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. 2005, 2, e73	2628
1760	Chemotherapy for metastatic NSCLC: current status and future direction. 2005, 2, 238-9	1
1759	Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer. 2005, 35, 233-8	9
1758	Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?. 2005, 97, 868-9	21
1757	When clinical trials are compromised: a perspective from a patient advocate. 2005, 2, e358	3
1756	Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. 2005, 11, 3032-7	113
1755	Ushering in the new toxicology: toxicogenomics and the public interest. 2005, 113, 818-22	7
1754	Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy. 2005, 2, e13	17
1753	EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head. 2005, 2, e75	18
1752	Inhibition of EGFR signaling: all mutations are not created equal. 2005, 2, e377	35
1751	Acquired gefitinib-resistant mutation of EGFR in a chemo-naïve lung adenocarcinoma harboring gefitinib-sensitive mutation L858R. 2005, 2, e269	22
1750	Development of oncology drug response markers using transcription profiling. 2005, 5, 103-10	6
1749	From traditional biomarkers to transcriptome analysis in drug development. 2005, 5, 29-38	34
1748	Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. 2005, 26, 1481-7	108
1747	Growth factor signal transduction defects in the cardiovascular system. 2005, 65, 574-80	12
1746	EGFR tyrosine kinase domain mutations in human gliomas. 2005, 64, 1444-5	62
1745	Targeted therapy: wave of the future. 2005, 23, 1776-81	46
1744	Molecule-kinase interaction map. 2005, 23, 1346; author reply 1346-8	4

1743	Pharmacogenomics steps toward personalized medicine. 2005 , 2, 325-337	60
1742	Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. 2005 , 65, 9176-84	157
1741	Improving cancer therapeutics by molecular profiling. 2005 , 6, 553-68	2
1740	Application of Pharmacogenomic Approaches in the Study of Drug Response in Complex Diseases. 2005 , 3, 177-190	
1739	Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?. 2005 , 23, 6813-6	54
1738	Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. 2005 , 65, 6943-9	82
1737	Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. 2005 , 2, e313	527
1736	A curious link between epidermal growth factor receptor amplification and survival: effect of "allele dilution" on gefitinib sensitivity?. 2005 , 97, 621-3	22
1735	High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. 2005 , 65, 11478-85	124
1734	Epidermal Growth Factor. 2005 ,	
1733	HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. 2005 , 65, 4253-60	97
1732	Gene expression profiling of human sarcomas: insights into sarcoma biology. 2005 , 65, 9226-35	287
1731	Somatic mutations of the protein kinase gene family in human lung cancer. 2005 , 65, 7591-5	392
1730	Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. 2005 , 65, 10524-35	71
1729	Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). 2005 , 65, 1770-7	197
1728	Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. 2005 , 11, 5539-48	234
1727	Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. 2005 , 11, 3750-7	269
1726	Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. 2005 , 11, 1572-8	75

1725	Translating research into cancer molecular diagnostics and patents. 2005 , 58, 793-4		1
1724	Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients. 2005 , 16, 934-41		65
1723	Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. 2005 , 23, 8396-405		110
1722	Development of strategies for the use of anti-growth factor treatments. 2005 , 12 Suppl 1, S173-82		30
1721	EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2005 , 353, 207-8	59.2	145
1720	Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. 2005 , 65, 7276-82		445
1719	A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. 2005 , 11, 3369-76		172
1718	Hereditary hormone excess: genes, molecular pathways, and syndromes. 2005 , 26, 615-61		64
1717	Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. 2005 , 11, 1983-9		114
1716	Use of positron emission tomography scans in ovarian cancer: a diagnostic technique in search of an indication. 2005 , 23, 7385-7		11
1715	Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. 2005 , 65, 11631-8		339
1714	Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor. 2005 , 4, 938-47		10
1713	Gefitinib versus cetuximab in lung cancer: round one. 2005 , 97, 1168-9		14
1712	Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. 2005 , 23, 3227-34		343
1711	Overview of tyrosine kinase inhibitors in clinical breast cancer. 2005 , 12 Suppl 1, S135-44		74
1710	HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. 2005 , 16, 538-48		39
1709	Pharmacogenetics in drug development. 2005 , 360, 1579-88		15
1708	Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. 2005 , 65, 6401-8		221

1707	Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. 2005 , 11, 8105-8	120
1706	One hundred years of lung cancer. 2005 , 172, 523-9	267
1705	Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. 2005 , 23, 3235-42	183
1704	Targeted therapy with imatinib: hits and misses?. 2005 , 23, 8-10	36
1703	Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. 2005 , 4, 1943-51	58
1702	In Reply:. 2005 , 23, 3866-3867	1
1701	In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. 2005 , 11, 7508-15	137
1700	Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. 2005 , 65, 5561-70	285
1699	Epidermal growth factor receptor expression in anal canal carcinoma. 2005 , 124, 20-3	54
1698	Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. 2005 , 4, 641-9	102
1697	Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. 2005 , 65, 4716-27	44
1696	Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). 2005 , 10, 579-89	100
1695	Inhibitors of growth factor signalling. 2005 , 12 Suppl 1, S183-7	43
1694	An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. 2005 , 65, 7096-101	231
1693	Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. 2005 , 16, 1906-14	52
1692	Lung cancer in women. 2005 , 23, 3212-8	121
1691	Pharmacogenetics in gastrointestinal tumors. 2005 , 28, 435-40	7
1690	AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. 2005 , 11, 1963-73	49

1689	Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib. 2005 , 11, 8872-9	29
1688	Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. 2005 , 280, 19625-34	130
1687	Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?. 2005 , 23, 5856-8	67
1686	An overview of lung cancer genomics and proteomics. 2005 , 32, 169-76	132
1685	Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target. 2005 , 23, 1791-3	37
1684	How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care. 2005 , 10 Suppl 2, 23-9	20
1683	Targeting HER1/EGFR in cancer therapy: experience with erlotinib. 2005 , 1, 449-60	17
1682	Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?. 2005 , 58, 700-4	79
1681	Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. 2005 , 11, 6924-32	277
1680	Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. 2005 , 65, 8853-60	75
1679	Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. 2005 , 23, 5323-33	286
1678	Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. 2005 , 16, 189-94	130
1677	Identification of the scaramanga gene implicates Neuregulin3 in mammary gland specification. 2005 , 19, 2078-90	58
1676	Developing an oncology portfolio of anticancer drugs: the experience of one pharmaceutical company. 2005 , 127, 385-8	
1675	Therapeutic potential of EGFR-related protein, a universal EGFR family antagonist. 2005 , 1, 235-45	12
1674	[Non-small-cell lung cancer third-line therapy with gefitinib]. 2005 , 59, 321-7	1
1673	Factors predicting response to EGFR tyrosine kinase inhibitors. 2005 , 26, 314-22	18
1672	Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment. 2005 , 26, 342-52	18

1671	The role of adjuvant chemotherapy for non-small cell lung cancer. 2005 , 26, 298-303		7
1670	Clinical year in review I: lung cancer, interventional pulmonology, noninvasive mask ventilation, and pulmonary vascular disease. 2005 , 2, 102-4		
1669	Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. 2005 , 237, 342-7		71
1668	Chapter 13 Targeting the Kinome with Computational Chemistry. 2005 , 185-202		2
1667	How will lung cancer be treated in the future?. 2005 , 1, 551-9		0
1666	Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. 2005 , 6, 873-7		39
1665	Epidermal growth factor receptor inhibitors in cancer treatment. 2005 , 1, 221-34		49
1664	Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity. 2005 , 5, 727-35		2
1663	Clinical advancement of EGFR inhibitors in cancer therapy. 2006 , 327, 189-202		6
1662	Erlotinib hydrochloride. 2005 , 4, S14-S15		18
1661	Pulmonary adenocarcinomas with mutant epidermal growth factor receptors. <i>New England Journal of Medicine</i> , 2005 , 352, 1724-5	59.2	8
1660	Responsiveness to cetuximab without mutations in EGFR. <i>New England Journal of Medicine</i> , 2005 , 353, 208-9	59.2	111
1659	Chasing mutations in the epidermal growth factor in lung cancer. <i>New England Journal of Medicine</i> , 2005 , 352, 830-2	59.2	29
1658	Targeting EGFR in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2005 , 353, 200-2	59.2	30
1657	Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors. <i>New England Journal of Medicine</i> , 2005 , 353, 209-10	59.2	29
1656	Inhibition of angiogenesis in cancer patients. 2005 , 10, 403-12		16
1655	Erlotinib in the treatment of non-small cell lung cancer. 2005 , 5, 767-75		18
1654	Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer. 2005 , 6, 603-14		12

1653	Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations. 2005 , 1, 319-22	
1652	Hepatocellular carcinoma: molecular pathways and new therapeutic targets. 2005 , 25, 212-25	222
1651	How Cancer Could be Cured by 2015. 2005 , 4, 268-277	35
1650	Genetic profiling of human hepatocellular carcinoma. 2005 , 25, 125-32	46
1649	New biological agents in the treatment of advanced non-small cell lung cancer. 2005 , 26, 323-32	3
1648	Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling. 2005 , 5, 487-99	26
1647	Chemoprevention of lung cancer: concepts and strategies. 2005 , 5, 549-65	4
1646	Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. 2005 , 2, 337-48	40
1645	Tyrannosaurus Rex revisited--will it survive?. 2005 , 1, 141-3	
1644	Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. 2005 , 4, 1381-6	33
1643	Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. 2005 , 23, 5568-77	418
1642	Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. 2005 , 102, 3395-400	283
1641	Epidermal growth factor inhibition in solid tumours. 2005 , 5, 1165-74	15
1640	Gefitinib in non-small cell lung cancer. 2005 , 6, 985-93	41
1639	Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly. 2005 , 10, 602-12	48
1638	Pharmacogenomic discovery approaches: will the real genes please stand up?. 2005 , 23, 7342-9	38
1637	Recent advances in targeted therapy of human myelogenous leukaemia. 2005 , 9, 1147-63	2
1636	Application of Apoptosis to Cancer Treatment. 2005 ,	

1635	ERBB2 in pediatric cancer: innocent until proven guilty. 2005 , 10, 508-17	25
1634	Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients. 2005 , 92, 1877-80	16
1633	ZD6474--clinical experience to date. 2005 , 92 Suppl 1, S14-20	55
1632	Targeted antitumour therapy--future perspectives. 2005 , 92 Suppl 1, S28-31	12
1631	Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors. 2005 , 92, 1063-8	43
1630	Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. 2005 , 93, 915-23	60
1629	Epidemiology informing clinical practice: from bills of mortality to population laboratories. 2005 , 2, 625-34	16
1628	Tumoral drug metabolism: overview and its implications for cancer therapy. 2005 , 23, 205-29	123
1627	Individualised cancer therapeutics: dream or reality?. 2005 , 9, 1189-201	7
1626	Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. 2005 , 93, 355-63	141
1625	EGFR inhibitors: what have we learned from the treatment of lung cancer?. 2005 , 2, 554-61	69
1624	Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. 2005 , 92, 1922-6	60
1623	Induction of cancer-specific cytotoxicity towards human prostate and skin cells using quercetin and ultrasound. 2005 , 92, 499-502	42
1622	Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. 2005 , 97, 339-46	1919
1621	Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. 2005 , 102, 1915-20	204
1620	Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. 2005 , 102, 7665-70	827
1619	Epidermal growth factor receptor inhibitors: a moving target?. 2005 , 11, 7203-5	16
1618	Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. 2005 , 23, 6657-63	390

1617	Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. 2005 , 11, 4289-94	107
1616	Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. 2005 , 23, 2502-12	302
1615	Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. 2005 , 11, 2398-407	80
1614	Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. 2005 , 65, 10371-80	90
1613	Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. 2005 , 102, 11011-6	487
1612	Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation. 2005 , 13, 319-27	36
1611	Design issues of randomized phase II trials and a proposal for phase II screening trials. 2005 , 23, 7199-206	279
1610	14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. 2005 , 23, 9105-12	111
1609	Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib. 2005 , 23, 7736-8	7
1608	Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. 2005 , 23, 6172-80	92
1607	Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. 2005 , 23, 2544-55	497
1606	Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. 2005 , 11, 7480-9	82
1605	FDA drug approval summary: erlotinib (Tarceva) tablets. 2005 , 10, 461-6	305
1604	Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice. 2005 , 11, 8789-98	40
1603	Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. 2005 , 10, 104-11	98
1602	Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. 2005 , 65, 4598-606	98
1601	Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?. 2005 , 23, 921-2; author reply 922	4
1600	ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. 2005 , 102, 3788-93	437

1599	Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. 2005 , 65, 9280-6	47
1598	Reply to the Letter to the Editor on Relevance of EGFR expression in colorectal cancer by C. Alliot (Ann Oncol 2005; 16: 1557). 2005 , 16, 1558-1559	
1597	Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. 2005 , 11, 7841-50	224
1596	Impact of EGFR expression on colorectal cancer patient prognosis and survival. 2005 , 16, 102-8	279
1595	Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. 2005 , 11, 8686-98	451
1594	Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. 2005 , 97, 1185-94	268
1593	10th annual meeting--Association for Molecular Pathology. 2005 , 5, 131-4	
1592	Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. 2005 , 23, 6838-45	513
1591	Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. 2005 , 10, 855-74	8
1590	Molecularly-targeted therapies for non-small cell lung cancer. 2005 , 6, 2667-79	5
1589	Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. 2005 , 65, 1642-6	569
1588	Genomic profiling of cancer: what next?. 2005 , 23, 7253-6	10
1587	Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies. 2005 , 65, 9415-25	44
1586	Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. 2005 , 97, 880-7	402
1585	Integration/Interaction of Oncologic Growth. 2005 ,	3
1584	Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer. 2005 , 25, 329-35	16
1583	Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. 2005 , 23, 5235-46	430
1582	Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. 2005 , 23, 3614-21	158

1581	Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. 2005 , 23, 866-73	374
1580	Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer. 2005 , 23, 235-7	10
1579	Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839. 2005 , 65, 2364-72	24
1578	Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. 2005 , 65, 6275-81	190
1577	Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes. 2005 , 65, 7137-44	119
1576	Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. 2005 , 11, 6177-85	93
1575	Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. 2005 , 11, 5631-8	43
1574	Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. 2005 , 4, 2008-15	62
1573	Impact of molecular pathology on the clinical management of lung cancer. 2005 , 72, 229-32	4
1572	Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. 2005 , 11, 8288-94	193
1571	In Reply:. 2005 , 23, 922-922	1
1570	The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. 2005 , 10, 467-70	60
1569	Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. 2005 , 65, 8968-74	145
1568	Bexarotene and erlotinib for aerodigestive tract cancer. 2005 , 23, 8757-64	58
1567	Raf kinase as a target for anticancer therapeutics. 2005 , 4, 677-85	221
1566	Implications of pharmacogenomics for drug development and clinical practice. 2005 , 165, 2331-6	47
1565	Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study. 2005 , 11, 8109-13	22
1564	Smoking, the missing drug interaction in clinical trials: ignoring the obvious. 2005 , 14, 2287-93	152

1563	Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. 2005 , 11, 2785-808	512
1562	Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. 2005 , 23, 9089-96	141
1561	In Reply:. 2005 , 23, 930-931	3
1560	Therapeutic targeting of receptor tyrosine kinases in lung cancer. 2005 , 9, 533-59	20
1559	The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. 2005 , 2, 341-51	41
1558	Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. 2005 , 65, 9751-61	133
1557	Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. 2005 , 11, 1368-71	124
1556	High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. 2005 , 11, 2894-8	10
1555	Membrane Receptor and Antiangiogenic Targeted Therapies in the Treatment of Cancer. 2005 , 1, 51-61	1
1554	Identifying Biomarkers of Lung Cancer in the Post-Genomic Era. 2005 , 3, 319-331	2
1553	Molecularly targeted therapy for gastrointestinal cancer. 2005 , 5, 171-93	73
1552	Relevance of EGFR expression in colorectal cancer. 2005 , 16, 1557-8; author reply 1558-9	2
1551	Epithelial membrane protein-1 is a biomarker of gefitinib resistance. 2005 , 102, 11858-63	74
1550	Novel targeted therapies in the treatment of gastric and esophageal cancer. 2005 , 16, 1740-8	59
1549	EGFR gene mutations: a call for global x global views of cancer. 2005 , 97, 326-8	23
1548	Study design issues and early stage non-small cell lung cancer. 2005 , 11, 5030s-5032s	2
1547	Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. 2005 , 11, 2300-4	221
1546	The ErbB receptors and their ligands in cancer: an overview. 2005 , 6, 243-57	234

1545	Interferon-alpha promotes the anti-proliferative effect of gefitinib (ZD 1839) on human colon cancer cell lines. 2005 , 69, 224-38	13
1544	Acute myocardial infarction with lung cancer during treatment with gefitinib: the possibility of gefitinib-induced thrombosis. 2005 , 34, 48-50	6
1543	[Basic principles of signal transduction]. 2005 , 28 Suppl 4, 14-7	2
1542	[Clinical development of targeted molecular cancer drugs]. 2005 , 28 Suppl 4, 35-9	3
1541	Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program. 2005 , 28, 195-8	7
1540	Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro. 2005 , 68, 538-47	37
1539	Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines -- implications for clinical use. 2005 , 28, 482-8	4
1538	EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients. 2005 , 28, 623-7	3
1537	[EGF receptor blockade with monoclonal antibodies and so-called "small molecules"]. 2005 , 28 Suppl 4, 18-24	5
1536	Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. 2005 , 1, 461-6	6
1535	2004: Signaling Breakthroughs of the Year. 2005 , 2005, eg1-eg1	
1534	Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. 2005 , 65, 1778-82	111
1533	Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. 2005 , 11, 6226-32	32
1532	Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. 2005 , 11, 6650-6	132
1531	Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. 2005 , 23, 9265-74	122
1530	Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. 2006 , 125, 860-5	35
1529	Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. 2005 , 4, 435-42	94
1528	Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?. 2005 , 4, 1096-7	4

1527	Modulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines. 2005 , 4, 1089-95	10
1526	A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment. 2005 , 4, 400-6	30
1525	Met activation and receptor dimerization in cancer: a role for the Sema domain. 2005 , 4, 683-5	31
1524	Molecular targeted therapy for lung cancer. 2005 , 366, 1507-8	7
1523	Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). 2005 , 366, 1527-37	1802
1522	RNA interference and nonviral targeted gene therapy of experimental brain cancer. 2005 , 2, 139-50	41
1521	Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. 2005 , 11, 2879-82	227
1520	Role of nuclear receptors in lung tumourigenesis. 2005 , 41, 2561-8	29
1519	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. 2005 , 6, 279-86	833
1518	Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance. 2005 , 6, 589-98	37
1517	Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. 2005 , 76, 162-7	81
1516	Optimizing chemotherapy and targeted agent combinations in NSCLC. 2005 , 50, S25-S32	17
1515	Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. 2005 , 24, 3512-24	81
1514	Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?. 2005 , 49, 1-12	117
1513	Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. 2005 , 23, 9359-68	286
1512	Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. 2005 , 50, 375-84	136
1511	Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. 2005 , 23, 8081-92	551
1510	Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. 2005 , 23, 6829-37	641

1509	The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. 2005 , 16, 1334-42	78
1508	Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. 2005 , 23, 5007-18	333
1507	Erlotinib in lung cancer - molecular and clinical predictors of outcome. <i>New England Journal of Medicine</i> , 2005 , 353, 133-44	59.2 1594
1506	Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. 2005 , 97, 643-55	1367
1505	Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. 2005 , 23, 2513-20	839
1504	Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. 2005 , 23, 2493-501	681
1503	Race, gender and mutations in the prediction of anti-EGFR activity. 2005 , 1, 201-4	
1502	Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. 2005 , 11, 2106-10	133
1501	EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. 2005 , 23, 857-65	692
1500	[New therapeutic approaches in glioblastomas]. 2005 , 161, 267-73	
1499	Perspectives thérapeutiques du cancer bronchique. 2005 , 22, 93-94	
1498	Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. 2005 , 7, 396-403	200
1497	Le carcinome bronchiolo-alvéolaire. 2005 , 22, 70-75	3
1496	Clinical applications for targeted therapy in bladder cancer. 2005 , 32, 239-46, vii	6
1495	Lung: Medical Oncology. 2005 , 16, P8-P11	
1494	Targeted therapies for prostate cancer. 2005 , 9, 283-98	10
1493	Overcoming Acquired Resistance to Iressa/Tarceva with Inhibitors of a Different Class. 2005 , 4, 4057-4059	11
1492	Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004. 2005 , 6, 1269-75	

1491	Erlotinib in non-small cell lung cancer: a review. 2005 , 6, 995-1002	8
1490	Perspectives on novel therapies for bronchial carcinoma. 2005 , 6, 1157-67	5
1489	Mining the tumor phosphoproteome for cancer markers. 2005 , 11, 3163-9	74
1488	Second-generation kinase inhibitors. 2005 , 9, 975-93	48
1487	Novel therapeutics in adult malignant brain gliomas. 2005 , 14, 643-58	4
1486	LightTyper platform for high-throughput clinical genotyping. 2005 , 5, 457-71	9
1485	Mouse models for human lung cancer. 2005 , 19, 643-64	228
1484	Predictive markers in breast and other cancers: a review. 2005 , 51, 494-503	128
1483	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. 2005 , 23, 5900-9	1250
1482	Genomics and the second golden era of cancer drug development. 2005 , 1, 17-26	43
1481	State of the art in therapy for non-small cell lung cancer. 2005 , 23, 427-42	58
1480	The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?. 2005 , 9, 1009-30	45
1479	Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. 2005 , 23, 2445-59	613
1478	Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases. 2005 , 5, 101-12	11
1477	Spotlight on gefitinib in non-small-cell lung cancer. 2005 , 5, 133-6	4
1476	EGFR pharmacogenomics: the story continues to mutate and evolve. 2005 , 5, 137-9	1
1475	Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer. 2005 , 5, 141-8	17
1474	Cancer diagnostics: decision criteria for marker utilization in the clinic. 2005 , 5, 357-64	22

1473	Receptor-targeted cancer therapy. 2005 , 24, 271-82	27
1472	Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. 2005 , 280, 10025-33	74
1471	What is targeted therapy?. 2005 , 23, 1614-5	68
1470	Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. 2005 , 11, 5878-85	295
1469	Predictors of the response to gefitinib in refractory non-small cell lung cancer. 2005 , 11, 2244-51	161
1468	Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. 2005 , 16, 780-5	69
1467	Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. 2005 , 11, 6414-21	182
1466	TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. 2005 , 23, 5892-9	1267
1465	Pharmacogenetics and Drug Development. 2005 , 417-427	
1464	Phosphoproteomics for oncology discovery and treatment. 2005 , 9, 851-60	9
1463	A historical perspective of the EGF receptor and related systems. 2006 , 327, 1-24	41
1462	Role of tyrosine kinase inhibitors in cancer therapy. 2005 , 315, 971-9	713
1461	Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. 2005 , 23, 3219-26	78
1460	Cyclin D1 in breast cancer pathogenesis. 2005 , 23, 4215-24	317
1459	An identity crisis for fps/fes: oncogene or tumor suppressor?. 2005 , 65, 3518-22	27
1458	Pharmacogenetics/genomics and personalized medicine. 2005 , 14 Spec No. 2, R207-14	140
1457	Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. 2005 , 65, 1479-88	470
1456	Tyrosine kinases as targets for cancer therapy. <i>New England Journal of Medicine</i> , 2005 , 353, 172-87	59.2 1084

1455	The progress and promise of molecular imaging probes in oncologic drug development. 2005 , 11, 7967-85	194
1454	High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding. 2005 , 352, 1134-56	38
1453	Targeted therapy for colorectal cancer: mapping the way. 2005 , 11, 327-35	16
1452	Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. 2005 , 95, 173-81	52
1451	Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. 2005 , 36, 486-93	198
1450	Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. 2005 , 36, 1127-34	48
1449	Mutational analysis of gene families in human cancer. 2005 , 15, 5-12	40
1448	Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. 2005 , 27, 1513-34	82
1447	Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. 2005 , 5, 350-6	185
1446	Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. 2005 , 8, 15-26	111
1445	Resistance to tyrosine kinase inhibitors: calling on extra forces. 2005 , 8, 119-29	33
1444	Resistance to epidermal growth factor receptor-targeted therapy. 2005 , 8, 298-310	66
1443	How to develop a successful cancer drug--molecules to medicines or targets to treatments?. 2005 , 41, 676-82	34
1442	Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. 2005 , 41, 1286-90	44
1441	Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?. 2005 , 41, 1383-92	91
1440	Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines. 2005 , 41, 2338-46	30
1439	Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. 2005 , 224, 117-21	45
1438	Antitumor activity of HER-2 inhibitors. 2005 , 227, 9-23	77

1437	Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer. 2005 , 230, 33-46	32
1436	[New strategies to interfere with radiation response: "biomodulation" of radiation therapy]. 2005 , 9, 69-76	6
1435	Identification of cancer genes by mutational profiling of tumor genomes. 2005 , 579, 1884-90	20
1434	The future of antidepressant pharmacogenetics is arriving. Introduction. 2005 , 29, 996-8	1
1433	How can I adapt to a rapidly changing world?. 2005 , 64, 550-2	
1432	Overcoming limitations of natural anticancer drugs by combining with artificial agents. 2005 , 26, 77-81	56
1431	Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer. 2005 , 99, 298-307	13
1430	Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. 2005 , 23, 3279-87	223
1429	Roadmap for developing and validating therapeutically relevant genomic classifiers. 2005 , 23, 7332-41	324
1428	Interstitial lung disease in lung cancer: separating disease progression from treatment effects. 2005 , 28, 103-13	52
1427	Epidermal Growth Factor Receptor as a Target for Chemotherapy. 2005 , 5, S19-S27	47
1426	Cetuximab in previously treated colorectal cancer. 2005 , 5 Suppl 1, S28-33	8
1425	Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer. 2005 , 5 Suppl 2, S62-70	9
1424	Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. 2005 , 5 Suppl 2, S71-80	20
1423	Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer. 2005 , 5 Suppl 2, S81-8	7
1422	Genetic alterations in prostate cancer. 2005 , 3, 220-9	1
1421	Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005?. 2005 , 7, 175-9	6
1420	Allele-specific amplification in cancer revealed by SNP array analysis. 2005 , 1, e65	92

1419	Mutated kinases as targets for cancer drugs. 2005 , 2, 139-144	7
1418	Mechanisms of lung cancer. 2005 , 2, 213-223	14
1417	Targeted therapy in colorectal cancer: do we know enough?. 2006 , 38, 71-7	5
1416	Biologie des cancers bronchiques. 2005 , 2, 9-31	
1415	Is there a relationship between c-erbB-1 and c-erbB-2 amplification and protein overexpression in NSCLC?. 2005 , 47, 325-36	18
1414	Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer. 2005 , 48, 141-4	36
1413	Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. 2005 , 47, 69-80	243
1412	Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America. 2005 , 49, 225-31	44
1411	HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients. 2005 , 49, 279-80	3
1410	EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report. 2005 , 49, 413-5	22
1409	Gefitinib in patients with non-small cell lung cancer: symptomatic improvement within a few days. 2005 , 49, 417-8	3
1408	Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. 2005 , 50, 1-8	105
1407	A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). 2005 , 50, 91-6	38
1406	Consensus on medical treatment of non-small-cell lung cancer—update 2004. 2005 , 50, 129-137	2
1405	Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation. 2005 , 50, 259-63	8
1404	Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. 2005 , 50, 25-33	70
1403	Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. 2005 , 50, 385-91	33
1402	Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. 2005 , 50, 417-8	29

1401	Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study. 2005 , 50, 413-5		9
1400	EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. <i>New England Journal of Medicine</i> , 2005 , 352, 786-92	59.2	3250
1399	Chapter 1 Emerging technologiesThe way forward on improving protein analysis. 2005 , 1-67		1
1398	Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. <i>New England Journal of Medicine</i> , 2005 , 353, 2012-24	59.2	1211
1397	Novel therapies in lung cancer. 2005 , 19, 343-67, vii		4
1396	Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice. 2005 , 7, 696-704		25
1395	Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. 2005 , 7, 426-31		47
1394	Epidemiology of lung cancer: looking to the future. 2005 , 23, 3175-85		336
1393	Pathogenesis of lung cancer: 100 year report. 2005 , 33, 216-23		104
1392	Current Advancements in Hard-To-Treat Cancers. 2005 , 4, 105-113		0
1391	Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. 2005 , 92, 1110-6		58
1390	Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. 2005 , 11, 6816-22		125
1389	Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. 2005 , 23, 2556-68		525
1388	Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. 2005 , 45, 357-84		107
1387	Intracellular signal transduction pathway proteins as targets for cancer therapy. 2005 , 23, 5386-403		155
1386	Renal-cell carcinoma. <i>New England Journal of Medicine</i> , 2005 , 353, 2477-90	59.2	1231
1385	Erlotinib in previously treated non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2005 , 353, 123-32	59.2	4590
1384	High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. 2005 , 7, R1186-98		164

1383	Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. 2005 , 7, R1028-35	116
1382	Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. 2005 , 7, R570-9	94
1381	Genetics of soft tissue tumors. 2006 , 1, 435-66	28
1380	Mutation of the PIK3CA oncogene in human cancers. 2006 , 94, 455-9	372
1379	Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. 2006 , 3, 448-57	552
1378	A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. 2006 , 95, 998-1004	244
1377	Taxanes in the treatment of non-small cell lung cancer. 2006 , 5, 181-91	5
1376	Epidermal Growth Factor Receptor Antagonists in Pancreatic Cancer. 2006 , 5, 213-221	1
1375	Lung cancer preneoplasia. 2006 , 1, 331-48	150
1374	Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation. 2006 , 8, 817-25	44
1373	Epidermal growth factor receptor biology in head and neck cancer. 2006 , 24, 2666-72	519
1372	The place of targeted therapies in the management of non-small cell bronchial carcinoma. 2006 , 23, 137-147	2
1371	Epidermal growth factor receptor status in anaplastic thyroid carcinoma. 2007 , 60, 881-4	31
1370	Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. 2006 , 3, 269-80	756
1369	Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. 2006 , 95, 1070-5	41
1368	Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. 2006 , 95, 1483-9	148
1367	Pharmacogenomics: challenges and opportunities. 2006 , 145, 749-57	181
1366	Cancer Drug Resistance. 2006 ,	17

1365	Pharmacodynamic biomarkers for molecular cancer therapeutics. 2007 , 96, 213-68	124
1364	Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. 2006 , 98, 15-25	233
1363	Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm. 2006 , 10, 67-76	32
1362	Epidermal growth factor receptor as a major anticancer drug target. 2006 , 10, 877-88	6
1361	Prevention of breast cancer: current state of the science and future opportunities. 2006 , 15, 1583-600	18
1360	Should every lung cancer patient be tested for EGFR mutation?. 2006 , 10, 789-91	1
1359	Is EGFR expression important in non-small cell lung cancer?. 2006 , 61, 98-9	33
1358	Cancer therapies targeted to the epidermal growth factor receptor and its family members. 2006 , 16, 147-164	3
1357	Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. 2006 , 24, 310-7	39
1356	The wind of change in the therapy of lung cancer. 2006 , 6, 469-72	
1355	Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. 2006 , 11, 274-84	78
1354	Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. 2006 , 66, 1371-5	130
1353	Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. 2006 , 24, 1924-31	543
1352	Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. 2006 , 24, 5034-42	623
1351	Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. 2006 , 24, 3340-6	449
1350	Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer. 2006 , 36, 344-50	25
1349	Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. 2006 , 52, 225-33	26
1348	Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. 2006 , 24, 1700-4	184

1347	A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. 2006 , 36, 69-75	61
1346	First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. 2006 , 24, 64-9	147
1345	Tyrphostins and other tyrosine kinase inhibitors. 2006 , 75, 93-109	180
1344	Keynote comment: reimbursement for molecularly targeted anticancer agents. 2006 , 7, 2-3	4
1343	Comparative pharmacogenomics of antiretroviral and cytotoxic treatments. 2006 , 7, 61-8	9
1342	Where next for gefitinib in patients with lung cancer?. 2006 , 7, 499-507	101
1341	Cancro do pulmão na mulher: Uma entidade diferente?. 2006 , 12, 545-561	
1340	Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. 2006 , 5, 1799-810	168
1339	Pharmacogenetics, pharmacogenomics and personalized medicine: are we there yet?. 2006 , 2006, 111-7	31
1338	472 POSTER Development of a 300,000 base pair custom sequencing microarray for biomarker discovery and anticancer drug development. 2006 , 4, 144-145	
1337	473 POSTER p53-dependent repression of CHEK1 contributes to apoptosis in colorectal cancer cells: an in vitro and in vivo study. 2006 , 4, 145	
1336	474 POSTER Inhibition of PDGFR-beta increases sarcoma cell sensitivity to tumor necrosis factor related apoptosis inducing ligand, TRAIL and promotes inhibition of tumor growth in dual therapy using imantinib (Gleevec) and TRAIL. 2006 , 4, 145	
1335	475 POSTER Involvement of the multi-ligand cell surface receptor RAGE in Tumor Necrosis Factor-induced cell death. 2006 , 4, 145-146	
1334	Pharmacogenetics and pharmacogenomics: development, science, and translation. 2006 , 7, 223-45	149
1333	Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbix) results in paradox phosphorylation of tyrosine 1173 in the receptor. 2006 , 580, 4793-800	27
1332	Multi-modality molecular imaging of tumors. 2006 , 20, 1215-48	7
1331	Pharmacogenomics in inflammatory bowel disease. 2006 , 4, 21-8	25
1330	Pouvons-nous sortir de l'ère du « tout chimiothérapie » ? Les nouvelles thérapies ciblées dans le traitement des cancers bronchiques non ^petites cellules. 2006 , 23, 23-26	

- 1329 Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain. **2006**, 8, 351-6 32
- 1328 De l'ASCO et du WCLC 2005 à la pratique clinique : thérapies ciblées. **2006**, 62, 30-34
- 1327 Formes cliniques des cancers thoraciques. **2006**, 23, 158-163 1
- 1326 Recent advances in the treatment of malignant astrocytoma. **2006**, 24, 1253-65 258
- 1325 Targeting tyrosine kinases in cancer: the second wave. **2006**, 312, 1175-8 380
- 1324 Est-il nécessaire de sélectionner les patients pour prescrire des thérapies ciblées dans les cancers bronchiques non à petites cellules de stade IV ? **2006**, 62, 41-44
- 1323 La place des thérapies ciblées dans la prise en charge des CBNPC: Mécanismes biologiques de la carcinogenèse bronchique : d'une meilleure compréhension naissent les nouvelles thérapies. **2006**, 23, 123-130
- 1322 Clinical trials in a molecular world. **2006**, 16, 681-94, ix 3
- 1321 Novel therapies targeting signaling pathways in lung cancer. **2006**, 16, 379-96, vi 10
- 1320 La place des thérapies ciblées dans la prise en charge des CBNPC. **2006**, 23, 148-157
- 1319 Novel targeted therapies for non-small cell lung cancer. **2006**, 16, 353-66 1
- 1318 Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. **2006**, 8, 504-12 37
- 1317 [Gefitinib treatment for carcinomatous meningitis in non-small cell lung cancer]. **2006**, 23, 149-51 1
- 1316 A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. **2006**, 8, 335-41 162
- 1315 The Basal Phenotype of BRCA1-Related Breast Cancer. **2006**, 17, 22-25
- 1314 Clinical implications of our advancing knowledge of colorectal cancer genetics: inherited syndromes, prognosis, prevention, screening and therapeutics. **2006**, 86, 787-817 19
- 1313 Thérapies ciblées et immunomodulation dans les tumeurs solides. **2006**, 15, 297-302
- 1312 Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. **2006**, 176, 787-92 29

1311	Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. 2006 , 66, 1441-63	11
1310	Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. 2006 , 6, 59-65	9
1309	Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. 2006 , 6, 208-13	15
1308	Bronchioloalveolar carcinoma: a review. 2006 , 7, 313-22	58
1307	Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. 2006 , 7, 385-8	112
1306	Lung cancer in women: exploring sex differences in susceptibility, biology, and therapeutic response. 2006 , 8, 22-9	19
1305	Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options. 2006 , 7 Suppl 4, S118-25	14
1304	Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. 2006 , 7 Suppl 4, S138-44	61
1303	Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors. 2006 , 49, 1475-85	72
1302	Adding pharmacogenomics to the development of new marine-derived anticancer agents. 2006 , 4, 3	11
1301	Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. 2006 , 1, 19	97
1300	Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. 2006 , 24, 2158-63	127
1299	Epidermal growth factor receptor is a critical mediator of ultraviolet B irradiation-induced signal transduction in immortalized human keratinocyte HaCaT cells. 2006 , 169, 823-30	59
1298	A review of erlotinib and its clinical use. 2006 , 7, 177-93	53
1297	Current status of cetuximab for the treatment of patients with solid tumors. 2006 , 40, 241-50	30
1296	Profiling the kinome for drug discovery. 2006 , 3, 269-76	3
1295	Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. 2006 , 51, 71-7	49
1294	EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. 2006 , 51, 363-8	65

1293	EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. 2006 , 51, 207-15	123
1292	Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. 2006 , 52, 93-7	84
1291	Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. 2006 , 52, 99-103	20
1290	Peptide ligands targeting integrin alpha3beta1 in non-small cell lung cancer. 2006 , 52, 291-7	28
1289	Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR. 2006 , 53, 13-21	19
1288	Three-year survival in metastatic non-small cell lung cancer treated with gefitinib. 2006 , 53, 123-4	5
1287	Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. 2006 , 53, 117-21	53
1286	Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients. 2006 , 53, 339-45	15
1285	L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer. 2006 , 54, 103-8	29
1284	Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. 2006 , 53, 311-22	64
1283	Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. 2006 , 54, 25-33	46
1282	EGFR genotyping in pleural fluid specimens in NSCLC patients. 2006 , 54, 265-6	3
1281	Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. 2006 , 54, 201-7	31
1280	Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. 2006 , 54, 193-9	32
1279	Assessment of molecular events in squamous and non-squamous cell lung carcinoma. 2006 , 54, 293-301	29
1278	Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. 2006 , 54, 387-98	88
1277	Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L. 2006 , 54, 419-22	50
1276	Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. 2006 , 24, 16-24	1408

1275	Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. 2006 , 66, 944-50	446
1274	Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. 2006 , 12, 5064-73	402
1273	Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. 2006 , 12, 6643-51	133
1272	A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. 2006 , 22, 561-73	77
1271	Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. 2006 , 24, 2549-56	305
1270	ErbB receptors and epithelial-cadherin-catenin complex in human carcinomas. 2006 , 2, 765-81	32
1269	Gefitinib prevents bleomycin-induced lung fibrosis in mice. 2006 , 174, 550-6	86
1268	Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. 2006 , 12, 4283-7	142
1267	A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer. 2006 , 94, 1599-603	33
1266	Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. 2006 , 10, 306-15	34
1265	Smoking status as a prognostic factor in patients with stage I pulmonary adenocarcinoma. 2006 , 81, 1189-93	68
1264	Molecular and genetic markers in thoracic surgery. 2006 , 82, 2335-6	
1263	Genetic testing for pharmacogenetics and its clinical application in drug therapy. 2006 , 363, 177-86	33
1262	Prognostic biomarkers in non-small-cell lung carcinoma. 2006 , 12, 418-428	7
1261	An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. 2006 , 125, 1137-49	1137
1260	Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. 2006 , 125, 1253-67	903
1259	mTOR and cancer: reason for dancing at the crossroads?. 2006 , 16, 78-84	60
1258	Epidermal growth factor receptor (EGFR) signaling in cancer. 2006 , 366, 2-16	1421

1257	Protein tyrosine kinase signaling diversity and susceptibility to targeted kinase inhibitors. 2006 , 60, 629-32	5
1256	The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. 2006 , 233, 328-37	30
1255	ERBB2 kinase domain mutation in the lung squamous cell carcinoma. 2006 , 237, 89-94	39
1254	High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand. 2006 , 239, 292-7	22
1253	Predicting the outcome of chemotherapy for lung cancer. 2006 , 6, 323-31	62
1252	Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. 2006 , 32, 74-89	137
1251	Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand?. 2006 , 32, 630-6	26
1250	Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy. 2006 , 42, 17-23	133
1249	Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. 2006 , 42, 109-11	142
1248	Targeted kinase inhibitors in lung cancer: from EGFR to patients. 2006 , 42, 124-5	
1247	(CA)n microsatellite polymorphism of ERBB-1 in breast cancer. 2006 , 42, 1698-701	2
1246	High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. 2006 , 37, 453-7	20
1245	BRAF and c-kit gene copy number in mutation-positive malignant melanoma. 2006 , 37, 520-7	84
1244	Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression. 2006 , 37, 755-63	56
1243	[Carcinoma of unknown primary site]. 2006 , 27, 532-45	4
1242	Interstitial lung disease associated with gefitinib. 2006 , 100, 698-704	30
1241	Setup and characterization of a human head and neck squamous cell carcinoma xenograft model in nude rats. 2006 , 135, 853-7	25
1240	Clinical experience with anti-EGFR therapy. 2006 , 22, 10-9	11

1239	Opiate and acetylcholine-independent analgesic actions of crotoxin isolated from crotalus durissus terrificus venom. 2006 , 48, 175-82	45
1238	Breast cancer. 2006 , 1, 187-210	2
1237	Epidermal growth factor receptor pathway inhibitors. 2006 , 1, 299-310	5
1236	Drugs for Lung Cancer Treatment. 2006 , 60, 123	
1235	Clinical Characteristics of Lung Cancer Diagnosed in Chonnam National University Hospital(CNUH) Since 2000. 2006 , 61, 427	5
1234	Antibody Therapy for Solid Tumors. 2006 , 433-444	
1233	Relation between ERCC1 Expression in Sputum and Survival after Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer. 2006 , 60, 151	
1232	Epidermal growth factor receptor-targeted agents for lung cancer. 2006 , 13, 129-40	16
1231	Authors' Reply. 2006 , 3, e207	5
1230	CLINICAL TRIAL DESIGNS FOR CYTOSTATIC AGENTS AND AGENTS DIRECTED AT NOVEL MOLECULAR TARGETS. 2006 , 365-378	
1229	Novel mutations of epidermal growth factor receptor in localized prostate cancer. 2006 , 11, 2518-25	35
1228	FARMACOGENTICA APLICADA AO CANCER. QUIMIOTERAPIA INDIVIDUALIZADA E ESPECIFICIDADE MOLECULAR. 2006 , 39, 577	1
1227	Intracellular Signaling in Cancer. 2006 ,	
1226	Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer. 2006 , 119, 63-68	6
1225	Bronchioloalveolar Carcinoma of the Lung. 2006 , 313-320	
1224	Contemporary Issues in the Systemic Treatment of Lung Cancer. 99-119	
1223	Overprotective Caregivers of Elderly Cancer Patients: A Case Report. 2006 , 92, 362-363	
1222	Precision weapons. 2006 , 6, S22-S23	

1221	Advances in malignant melanoma: genetic insights from mouse and man. 2006 , 11, 928-42	11
1220	Scatter Factors in Tumor Progression. 2006 , 111-142	
1219	EPIDERMAL GROWTH FACTORS. 2006 , 129-133	3
1218	The Trend Toward Personalized Medicine. 2006 ,	
1217	[Drug-induced lung diseases]. 2006 , 127, 425-32	5
1216	Kinase mutations in cancer: chinks in the enemy's armour?. 2006 , 18, 69-76	6
1215	Non-Small-Cell Lung Cancer. 2006 ,	
1214	EGF receptor testing for non-small cell lung carcinomas. 2006 , Chapter 10, Unit 10.9	1
1213	The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling events. 2006 , 396, 79-88	15
1212	ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications. 2006 , 107, 197-204	25
1211	In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib. 2006 , 397, 537-43	13
1210	Creating and enforcing patent rights in the fast moving field of personalized medicine. 2006 , 3, 89-94	0
1209	Second-Line Treatment of Non-small Cell Lung Cancer: Big Targets, Small Progress; Small Targets, Big Progress?. 2006 , 1, 927-928	3
1208	Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact. 2006 , 331, 139-49	10
1207	EGFR: A Prognostic and/or a Predictive Marker?. 2006 , 1, 395-397	4
1206	BAC Consensus Conference, November 4-6, 2004: Epidemiology, Pathogenesis, and Preclinical Models. 2006 , 1, S2-S7	2
1205	The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases. 2006 , 1, 344-359	29
1204	Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients. 2006 , 1, 520-525	21

1203	Molecular Biology, Genomics, and Proteomics in Bronchioloalveolar Carcinoma. 2006 , 1, S8-S12	4
1202	EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer. 2006 , 1, 406-412	20
1201	Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines. 2006 , 15, 1205	2
1200	A Literature Review of Molecular Markers Predictive of Clinical Response to Cytotoxic Chemotherapy in Patients with Lung Cancer. 2006 , 1, 31-37	16
1199	Genome-wide cDNA microarray screening of genes related to survival in patients after curative resection of non-small cell lung cancer. 2006 , 16, 817	
1198	Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review. 2006 , 1, 367-376	24
1197	Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary Adenocarcinoma. 2006 , 1, 413-416	34
1196	Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer. 2006 , 1, 740-743	2
1195	PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients. 2006 , 1, 629-634	25
1194	Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy. 2006 , 16, 533	1
1193	Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer. 2006 , 29, 615-23	6
1192	[Lung cancer in women: a different entity?]. 2006 , 12, 545-61	
1191	EGF Receptor Gene Mutations Are Common in Lung Cancers From Never Smokers and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib. 2006 , 2006, 132-134	
1190	Second-Line Treatment of Non-small Cell Lung Cancer: Big Targets, Small Progress; Small Targets, Big Progress?. 2006 , 1, 927-928	6
1189	A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. 2006 , 1, 1010-1019	1
1188	Second-line chemotherapy for non-small cell lung cancer. 2006 , 129, 840-2	3
1187	EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. 2006 , 1, 260-7	60
1186	Angled forceps used for transbronchial biopsy in which standard forceps are difficult to manipulate: a comparative study. 2006 , 129, 725-33	8

1185	Clinico-Pathological and Biological Significance of Tyrosine Kinase Domain Gene Mutations and Overexpression of Epidermal Growth Factor Receptor for Lung Adenocarcinoma. 2006 , 1, 787-795	6
1184	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non-Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. 2006 , 1, 52-60	
1183	Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review. 2006 , 1, 367-376	28
1182	PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients. 2006 , 1, 629-634	62
1181	The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases. 2006 , 1, 344-359	62
1180	Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary Adenocarcinoma. 2006 , 1, 413-416	54
1179	Monoclonal antibodies against epidermal growth factor receptor in advanced colorectal carcinoma: clinical efficacy and markers of sensitivity. 2006 , 1, 113-8	3
1178	Rational Development of Targeted Cancer Therapies Using Biomarkers. 2006 , 37, 482-489	
1177	Investigating the molecular basis of drug action and response: chemocentric genomics and proteomics. 2006 , 7, 387-95	5
1176	Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer. 2006 , 1, 113-131	9
1175	Targeting Prenylated RAS Modifying Enzymes in Cancer Cells. 2006 , 1, 285-293	1
1174	Signal Transduction Therapy for Cancer - Whither Now?. 2006 , 1, 1-12	11
1173	Genetic alterations in primary glioblastomas in Japan. 2006 , 65, 12-8	25
1172	Gefitinib Therapy for Pulmonary Adenocarcinoma With EGFR Mutation Diagnosed by Transbronchial Lung Biopsy Using Endobronchial Ultrasonography With Guide Sheath. 2006 , 13, 201-203	1
1171	BAC Consensus Conference, November 4 th , 2004: Epidemiology, Pathogenesis, and Preclinical Models. 2006 , 1, S2-S7	1
1170	Monitoring EGFR-mutant lung cancers by means of the blood. 2006 , 1, 199-200	1
1169	Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. 2006 , 1, 231-9	102
1168	EGFR: A Prognostic and/or a Predictive Marker?. 2006 , 1, 395-397	7

1167	EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer. 2006 , 1, 406-412	34
1166	Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. 2006 , 5, 1361-8	63
1165	Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients. 2006 , 1, 520-525	29
1164	Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer. 2006 , 1, 635-647	3
1163	Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer. 2006 , 1, 740-743	4
1162	The Role of Gefitinib Treatment for Korean Never-Smokers with Advanced or Metastatic Adenocarcinoma of the Lung: A Prospective Study. 2006 , 1, 965-971	11
1161	A simple and sensitive method for detecting major mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene in non-small-cell lung carcinoma. 2006 , 15, 101-8	28
1160	Rapid detection of epidermal growth factor receptor mutations in non-small cell lung cancer using real-time polymerase chain reaction with TaqMan-MGB probes. 2006 , 12, 33-9	21
1159	Erlotinib in-Previously Treated Non-Small-Cell Lung Cancer. 2006 , 2006, 231-233	1
1158	Molecular Biology, Genomics, and Proteomics in Bronchioloalveolar Carcinoma. 2006 , 1, S8-S12	10
1157	A Literature Review of Molecular Markers Predictive of Clinical Response to Cytotoxic Chemotherapy in Patients with Lung Cancer. 2006 , 1, 31-37	13
1156	Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). 2006 , 1, 1-13	38
1155	Matching patients with drugs: triumphs and challenges. 2006 , 3, 335-344	2
1154	Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. 2006 , 18, 341-6	36
1153	Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. 2006 , 17, 783-95	46
1152	Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents. 2006 , 18, 247-52	15
1151	Recent new approaches to the treatment of head and neck cancer. 2006 , 17, 365-75	20
1150	Adequacy of colonoscopic biopsy specimens for molecular analysis: a comparative study with colectomy tissue. 2006 , 15, 162-8	7

1149	Challenges and opportunities of pharmacogenetics in drug development. 2006 , 3, 195-206	5
1148	Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. 2006 , 17, 95-102	32
1147	Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies). 2006 , 18, 307-15	9
1146	Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies. 2006 , 18, 609-14	3
1145	Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. 2006 , 16, 475-83	90
1144	Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. 2006 , 30, 1309-15	77
1143	Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. 2006 , 17, 401-9	117
1142	Clinical experience with erlotinib in non-small-cell lung cancer. 2006 , 42, 147-56	15
1141	Targeted Therapy: Genomic Approaches. 2006 ,	
1140	Translational research in academia and industry. 2006 , 231, 1685-9	6
1139	Effective silencing of EGFR with RNAi demonstrates non-EGFR dependent proliferation of glioma cells. 2006 , 28, 1531	0
1138	Advances in chemotherapy of non-small cell lung cancer. 2006 , 130, 1211-9	139
1137	Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK. 2006 , 83-132	1
1136	Gefitinib is effective against juvenile pilocytic astrocytoma in vitro. 2006 , 47, 293-8	5
1135	Therapy of multidrug resistant human prostate tumors in the prostate of nude mice by simultaneous targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor on tumor-associated endothelial cells. 2006 , 66, 1788-98	22
1134	Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations. 2006 , 65, 331-46	49
1133	Pharmacogenetics approach to therapeutics. 2006 , 33, 525-32	21
1132	Management of the elderly patient with advanced non-small cell lung cancer. 2006 , 60, 340-3	10

1131	Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors. 2006 , 97, 404-9	14
1130	Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis. 2006 , 97, 640-3	19
1129	Interfering with cell-survival signalling as a treatment strategy for prostate cancer. 2006 , 97, 1149-53	8
1128	A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. 2006 , 98, 763-9	48
1127	Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma. 2006 , 11, 287-91	6
1126	Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. 2006 , 11, 687-92	27
1125	Worldwide trends in lung cancer pathology. 2006 , 11, 533-8	98
1124	Gefitinib is an additional prognostic factor in metastatic lung adenocarcinoma: Response. 2006 , 11, 836-836	1
1123	Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk. 2006 , 11, 693-8	18
1122	Loss of p16 in recurrent malignant mixed müllerian tumors of the uterus. 2006 , 16, 1354-7	11
1121	Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy. 2006 , 16 Suppl 1, 152-65	41
1120	Targeting epidermal growth factor receptor in lung cancer: Perspective from the AsiaPacific region. 2006 , 2, 22-31	1
1119	A semiparametric empirical likelihood method for biased sampling schemes with auxiliary covariates. 2006 , 62, 1149-60	27
1118	Molecular diagnostics of non-small cell lung cancer using mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration. 2006 , 17, 3-9	10
1117	The role of pharmacogenetics in cancer therapeutics. 2006 , 62, 35-46	54
1116	Drug development in oncology: classical cytotoxics and molecularly targeted agents. 2006 , 62, 15-26	128
1115	New targets and challenges in the molecular therapeutics of cancer. 2006 , 62, 5-14	27
1114	Recent trends in the treatment of advanced lung cancer. 2006 , 97, 448-52	16

1113	High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. 2006 , 97, 642-8	120
1112	EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. 2006 , 97, 753-9	64
1111	Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. 2006 , 97, 1366-73	77
1110	Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival. 2006 , 32, 441-50	31
1109	A critical appraisal of prognostic and predictive factors for common lung cancers. 2006 , 48, 779-86	18
1108	Cancer biomarkers: a systems approach. 2006 , 24, 905-8	153
1107	The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. 2006 , 24, 985-95	108
1106	The genetics of health. 2006 , 38, 1095-8	41
1105	Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. 2006 , 12, 852-5	283
1104	Comparing antibody and small-molecule therapies for cancer. 2006 , 6, 714-27	531
1103	Lineage dependency and lineage-survival oncogenes in human cancer. 2006 , 6, 593-602	267
1102	Integration of EGFR inhibitors with radiochemotherapy. 2006 , 6, 876-85	233
1101	Impact of genetic diagnostics on drug development strategy. 2006 , 5, 459-62	10
1100	EGF-ERBB signalling: towards the systems level. 2006 , 7, 505-16	1572
1099	Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. 2006 , 94, 896-903	117
1098	Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. 2006 , 94, 1136-43	114
1097	EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. 2006 , 95, 1390-5	110
1096	Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. 2006 , 95, 1504-13	43

1095	Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. 2006 , 86, 981-6	66
1094	Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. 2006 , 19, 541-7	38
1093	Epithelial growth factor receptor status in primary and recurrent ovarian cancer. 2006 , 19, 607-10	61
1092	Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. 2006 , 19, 986-98	16
1091	Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. 2006 , 19, 1213-20	59
1090	The second wave in kinase cancer drugs. 2006 , 24, 127-30	51
1089	Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. 2006 , 25, 1205-15	111
1088	Comparative and integrative functional genomics of HCC. 2006 , 25, 3801-9	96
1087	Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4. 2006 , 25, 5664-72	17
1086	Designing prospective clinical pharmacogenomic (PG) trials: meeting report on drug development strategies to enhance therapeutic decision making. 2006 , 6, 89-94	16
1085	Use of genomic signatures in therapeutics development in oncology and other diseases. 2006 , 6, 166-73	118
1084	Epidermal growth factor receptor expression and activation in neuroendocrine tumours. 2006 , 18, 355-60	76
1083	Epidermal growth factor receptor directed therapy in head and neck cancer. 2006 , 57, 25-43	44
1082	Clinical experience with gefitinib: an update. 2006 , 58, 31-45	46
1081	Proteasome inhibitors in lung cancer. 2006 , 58, 177-89	52
1080	Multitargeted therapy: can promiscuity be praised in an era of political correctness?. 2006 , 59, 150-8	24
1079	Novel targets in gastric and esophageal cancer. 2006 , 59, 128-38	23
1078	Cetuximab in advanced non-small cell lung cancer. 2006 , 59, 139-49	16

1077	Kinase inhibitors in the treatment of renal cell carcinoma. 2006 , 60, 216-26	26
1076	In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells. 2006 , 16, 1969-74	64
1075	Radiobiology of breast cancer. 2006 , 18, 166-78	20
1074	Lymphangitis carcinomatosa as a potential predictor for a response to gefitinib. 2006 , 18, 573-4	0
1073	Prevalence of mutation in the epidermal growth factor receptor gene in Chinese patients with non-small cell lung cancer. 2006 , 18, 635	1
1072	Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. 2006 , 79, 197-205	115
1071	The mannose-binding lectin: a prototypic pattern recognition molecule. 2006 , 18, 16-23	149
1070	Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. 2006 , 66, 1391-8	27
1069	Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment. 2006 , 6, 733-54	36
1068	Lung Cancer. 2006 , 552-628	1
1067	Application of pharmacogenomics in clinical pharmacology. 2006 , 16, 89-99	38
1066	FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. 2006 , 25, 147-51	55
1065	Maspin expression and its clinical significance in non-small cell lung cancer. 2006 , 13, 1517-23	27
1064	Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety. 2006 , 23, 147-60	21
1063	Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. 2006 , 23, 489-98	41
1062	Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. 2006 , 46, 249-79	518
1061	Prediction of anticancer drug potency from expression of genes involved in growth factor signaling. 2006 , 23, 336-49	24
1060	Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. 2006 , 24, 291-7	60

1059	Pharmacogenetics in the management of breast cancer -- prospects for individualised treatment. 2006 , 5, 151-7	6
1058	Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. 2006 , 8, 141-50	106
1057	Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. 2006 , 8, 262-77	89
1056	ErbB receptor negative regulatory mechanisms: implications in cancer. 2006 , 11, 89-99	16
1055	Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. 2006 , 96, 209-15	24
1054	EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocation. 2006 , 95, 211-8	177
1053	Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting. 2007 , 81, 81-91	36
1052	Molekular zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms. 2006 , 12, 769-779	1
1051	Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. 2006 , 448, 788-96	78
1050	Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines. 2006 , 132, 150-8	55
1049	Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib. 2006 , 132, 719-25	15
1048	Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients. 2007 , 133, 93-102	17
1047	Current status and perspective of angiogenesis and antivasular therapeutic strategy: non-small cell lung cancer. 2006 , 11, 73-81	21
1046	Methodological aspects of current problems in target-based anticancer drug development. 2006 , 11, 167-75	17
1045	Biological and clinical implications of EGFR mutations in lung cancer. 2006 , 11, 190-8	169
1044	Resistance to gefitinib. 2006 , 11, 487-91	26
1043	Cancer management can be personalized? Cancer genomic research in China. 2006 , 5, 156-158	2
1042	Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas. 2006 , 24, 565-78	9

1041	A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. 2006 , 57, 533-9	48
1040	Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. 2006 , 58, 460-70	43
1039	Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. 2006 , 58, 577-84	38
1038	Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. 2007 , 59, 183-95	70
1037	Impact of EGFR mutations on treatment of non-small cell lung cancer. 2006 , 58, 5-9	3
1036	Defining clinically relevant molecular subsets of lung cancer. 2006 , 58 Suppl 1, s11-5	16
1035	Molecular classification of tumors with special reference to EGFR mutation in lung cancer. 2006 , 58, 17-23	6
1034	The impact and role of EGFR gene mutation on non-small cell lung cancer. 2006 , 58, 25-31	7
1033	Clinical development of EGFR-tyrosine kinase inhibitors in Japan. 2006 , 58, 33-37	1
1032	EGFR mutation in various tissues. 2006 , 58, 39-41	3
1031	[Current morphological diagnosis of malignant lung tumors]. 2006 , 27, 90-8	3
1030	[Therapy of malignant melanoma. First-, second- and pathogenesis-oriented third-line therapies]. 2006 , 57, 773-84	7
1029	Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. 2006 , 84, 671-81	109
1028	[Multi-targeting drugs and multi-drug targeting in metastatic renal cell carcinoma. Concept of co-inhibition of the epidermal growth]. 2006 , 45, 356-8	
1027	New antiangiogenetic agents and non-small cell lung cancer. 2006 , 60, 76-86	19
1026	Targeted therapies for patients with advanced colorectal cancer: focus on cetuximab. 2006 , 1, 2-12	2
1025	Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies. 2006 , 1, 23-33	1
1024	Targeted therapies in the treatment of advanced non-small cell lung cancer elderly patients. 2006 , 1, 13-22	1

1023	Differential expression of EGFR and TGF β in VHL-mutated renal cell carcinomas of the clear cell type: implications for targeted therapeutic approaches. 2006 , 1, 71-78	3
1022	Aims and difficulties of targeting. 2006 , 1, 69-70	
1021	Phase II combination of gefitinib and docetaxel for advanced or metastatic non-small cell lung cancer: clinical results and biological monitoring. 2006 , 1, 114-122	
1020	Clinical phosphoproteomic profiling for personalized targeted medicine using reverse phase protein microarray. 2006 , 1, 151	2
1019	Correlative studies in neuro-oncology trials: should they influence treatment?. 2006 , 8, 54-7	5
1018	Targeted molecular therapy of malignant gliomas. 2006 , 8, 58-70	28
1017	Therapeutic targets in melanoma: map kinase pathway. 2006 , 8, 400-5	17
1016	Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. 2006 , 7, 16-22	9
1015	Phosphoinositide 3-kinase: from viral oncoprotein to drug target. 2006 , 344, 131-8	37
1014	Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. 2006 , 101, 126-31	89
1013	Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study. 2006 , 101, 18-23	27
1012	Relevant molecular markers and targets. 2006 , 103, S6-S13	15
1011	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. 2006 , 9, 485-95	389
1010	EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. 2006 , 9, 421-3	41
1009	Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. 2006 , 10, 39-50	311
1008	Targeting ADAMS and ERBBs in lung cancer. 2006 , 10, 7-11	33
1007	A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. 2006 , 10, 425-35	198
1006	Ligand-independent and EGF receptor-supported transactivation: lessons from beta2-adrenergic receptor signalling. 2006 , 18, 1633-46	52

1005	The complexity of targeting EGFR signalling in cancer: from expression to turnover. 2006 , 1766, 120-39	106
1004	Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. 2006 , 1766, 217-29	27
1003	Pharmacogenetics of cancer chemotherapy. 2006 , 1766, 168-83	13
1002	Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. 2006 , 71, 1422-34	68
1001	Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. 2006 , 72, 941-8	38
1000	[Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma]. 2006 , 30, 1133-5	1
999	Respiratory medicine: anti-IgE therapy, lung cancer and pulmonary hypertension. 2006 , 34, 431-434	1
998	Geographic variation in the second-line treatment of non-small cell lung cancer. 2006 , 33, S39-44	6
997	Optimizing therapy in previously treated non-small cell lung cancer. 2006 , 33, S25-31	7
996	Use of novel second-line targeted therapies in non-small cell lung cancer. 2006 , 33, S9-16	21
995	Second-line treatment options in advanced non-small cell lung cancer: current status. 2006 , 33, S3-8	7
994	Epidermal growth factor receptor targeting in cancer. 2006 , 33, 369-85	560
993	New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. 2006 , 33, 407-20	209
992	Variation in the human genome and the inherited basis of common disease. 2006 , 33, S46-9	7
991	Neoadjuvant therapy in the treatment of solid tumors. 2006 , 43, 457-551	
990	Radiation combined with EGFR signal inhibitors: head and neck cancer focus. 2006 , 16, 38-44	67
989	Molecular targeted therapy: a strategy of disillusion or optimism?. 2006 , 147, 108-13	5
988	Carcinosarcoma of the colon: report of a case with morphological, ultrastructural and molecular analysis. 2006 , 6, 185	24

987	Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. 2006 , 6, 277	46
986	A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. 2006 , 6, 278	42
985	High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. 2006 , 6, 295	223
984	Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer. 2006 , 7, 273-5	44
983	A randomized phase II study of radiation therapy, pemetrexed, and carboplatin with or without cetuximab in stage III non-small-cell lung cancer. 2006 , 7, 285-7	15
982	Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. 2006 , 7, 326-31	27
981	PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. 2006 , 7, 417-9	46
980	The way forward: new drugs and new therapeutic strategies in lung cancer therapy. 2006 , 7 Suppl 4, S109-10	
979	Managing dermatologic toxicities of epidermal growth factor receptor inhibitors. 2006 , 8 Suppl 1, S15-22	12
978	Comparative analysis of cancer genes in the human and chimpanzee genomes. 2006 , 7, 15	67
977	Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. 2006 , 7, 289	52
976	Application of DETECTER, an evolutionary genomic tool to analyze genetic variation, to the cystic fibrosis gene family. 2006 , 7, 44	7
975	Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. 2006 , 97, 724-34	56
974	The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. 2006 , 207, 420-7	113
973	Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. 2006 , 209, 645-52	106
972	Successes and failures of the teachable moment: smoking cessation in cancer patients. 2006 , 106, 17-27	280
971	Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival. 2006 , 106, 693-702	24
970	Genetic alterations in urothelial bladder carcinoma: an updated review. 2006 , 106, 1205-16	58

969	Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. 2006 , 106, 2005-11	258
968	Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. 2006 , 106, 2200-7	120
967	A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. 2006 , 107, 1034-41	69
966	Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. 2006 , 107, 1207-18	153
965	Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer. 2006 , 107, 1866-72	3
964	Survival outcome and predictors of gefitinib antitumor activity in East Asian chemo-naïve patients with advanced nonsmall cell lung cancer. 2006 , 107, 1873-82	51
963	Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. 2006 , 107, 2858-65	45
962	Clinical applications of genomics in head and neck cancer. 2006 , 28, 360-8	10
961	Proteomics: clinical applications for head and neck squamous cell carcinoma. 2006 , 28, 549-58	14
960	Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. 2006 , 118, 521-2	48
959	Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidylinositol-3 kinase pathways in non-small cell lung cancer cells. 2006 , 118, 209-14	130
958	ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. 2006 , 118, 483-9	33
957	EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. 2006 , 118, 1173-80	219
956	Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. 2006 , 118, 963-9	130
955	Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations. 2006 , 118, 1068-9	18
954	Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. 2006 , 118, 257-62	507
953	Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. 2006 , 118, 1588-90	59
952	Somatic mutations of the ERBB4 kinase domain in human cancers. 2006 , 118, 1426-9	87

951	Homozygous deletion of p16INK4a and tobacco carcinogen exposure in nonsmall cell lung cancer. 2006 , 118, 1364-9	31
950	Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer. 2006 , 118, 1545-55	15
949	Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma. 2006 , 118, 2498-504	40
948	Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer. 2006 , 119, 727-34	16
947	Sex differences in risk of lung cancer: Expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts. 2006 , 119, 741-4	106
946	Frequent EGFR mutations in brain metastases of lung adenocarcinoma. 2006 , 119, 1491-4	152
945	Accuracy of epidermal growth factor receptor mutation analysis on the basis of small biopsy specimens in patients with nonsmall cell lung cancer. 2006 , 119, 1751-2	8
944	Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. 2006 , 119, 2586-91	148
943	Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. 2006 , 119, 2353-8	89
942	Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. 2006 , 119, 2557-66	99
941	Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models. 2007 , 120, 1141-9	15
940	Anti-angiogenic drugs: from bench to clinical trials. 2006 , 26, 483-530	126
939	Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. 2006 , 26, 569-94	101
938	The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers. 2006 , 93, 44-6	12
937	Fluorine-18 labeling of ML04 [presently the most promising irreversible inhibitor candidate for visualization of EGFR in cancer. 2006 , 49, 533-543	17
936	Multiple-criterion evaluation of reported mutations: a proposed scoring system for the intragenic somatic mutation literature. 2006 , 5, 360-70	13
935	Past, present and future of gene expression-tailored therapy for lung cancer. 2006 , 3, 165-175	3
934	EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer. 2006 , 3, 170-1	16

933	EGFR targeted therapy: view from biological standpoint. 2006 , 5, 2072-6	27
932	The basal phenotype of BRCA1-related breast cancer: past, present and future. 2006 , 5, 963-7	43
931	Detecting low-abundance p16 and p53 mutations in pancreatic juice using a novel assay: heteroduplex analysis of limiting dilution PCRs. 2006 , 5, 1392-9	15
930	Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. 2006 , 5, 152-5	25
929	Elegance, silence and nonsense in the mutations literature for solid tumors. 2006 , 5, 349-59	20
928	Oncogenic shock: turning an activated kinase against the tumor cell. 2006 , 5, 2878-80	32
927	Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. 2006 , 84, 42-8	29
926	C-fos assessment as a marker of anti-epidermal growth factor receptor effect. 2006 , 66, 2385-90	28
925	Cancer risk assessment at the atomic level. 2006 , 66, 1897-9	14
924	EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. 2006 , 66, 3197-204	229
923	Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. 2006 , 66, 11389-98	98
922	Developing gene expression signatures of pathway deregulation in tumors. 2006 , 5, 2444-9	27
921	Her2-targeted therapies in non-small cell lung cancer. 2006 , 12, 4377s-4383s	54
920	Overexpression of glycosylphosphatidylinositol (GPI) transamidase subunits phosphatidylinositol glycan class T and/or GPI anchor attachment 1 induces tumorigenesis and contributes to invasion in human breast cancer. 2006 , 66, 9829-36	48
919	Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. 2006 , 24, 1428-34	129
918	Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question. 2006 , 24, 2225-6	16
917	Biological agents versus chemotherapy in the treatment of colorectal cancer. 2006 , 7, 1251-71	2
916	Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. 2006 , 17, 981-5	101

915	STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. 2006 , 16, 1149-58	131
914	Point mutations of protein kinases and individualised cancer therapy. 2006 , 7, 2243-61	23
913	The second annual symposium on the future of lung cancer: a translational focus. 11-12 November 2005, Washington D.C., USA. 2006 , 10, 475-80	
912	Treatment options and individualized medicine. 2007 , 361, 327-40	5
911	Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. 2006 , 91, 3662-6	53
910	Expression biomarkers for clinical efficacy and outcome prediction in cancer. 2006 , 7, 105-15	10
909	Recent Clinical Trials in Non-Small Cell Lung Cancer. 2006 , 2, 81-99	
908	Epithelial-mesenchymal transition in lung cancer: is tobacco the "smoking gun"?. 2006 , 35, 3-9	60
907	Der Einfluss genetischer Polymorphismen auf die Wirksamkeit von Medikamenten unter besonderer Berücksichtigung onkologischer Therapien. 2006 , 38, 16-21	
906	Tumorspezifische Therapien auch auf der Palliativstation? - Eine alte Frage neu beleuchtet. 2006 , 7, 19-24	1
905	Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma. 2006 , 8, 215-26	73
904	Update in lung cancer 2005. 2006 , 173, 695-7	6
903	EUS-FNA and biomarkers for the staging of non-small cell lung cancer. 2006 , 38 Suppl 1, S114-7	9
902	Overview of the pharmacoeconomics of pharmacogenetics. 2006 , 7, 1175-84	31
901	Which drugs for which patients?. 2006 , 2, 317-9	
900	Tailor-made chemotherapy for non-small cell lung cancer patients. 2006 , 2, 289-99	15
899	Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs. 2006 , 67, 633-41	13
898	New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children. 2006 , 2, 675-85	7

897	Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future. 2006 , 6, 709-16		4
896	Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain. 2006 , 15, 669-90		18
895	Gefitinib-sensitizing mutations in esophageal carcinoma. <i>New England Journal of Medicine</i> , 2006 , 354, 2193-4	59.2	43
894	Magnetic resonance imaging for the detection of myocardial fibrosis in scleroderma. <i>New England Journal of Medicine</i> , 2006 , 354, 2194-6	59.2	20
893	Pharmacogenomics: from bedside to clinical practice. 2006 , 15 Spec No 1, R89-93		59
892	An in vivo platform for translational drug development in pancreatic cancer. 2006 , 12, 4652-61		364
891	Translating genomic biomarkers into clinically useful diagnostics. 2006 , 6, 179-91		46
890	Dynamics of biological systems: role of systems biology in medical research. 2006 , 6, 891-902		42
889	Schizophrenia: do the genetics and neurobiology of neuregulin provide a pathogenesis model?. 2006 , 14, 64-77		8
888	Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. 2006 , 12, 6049-55		173
887	Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. 2006 , 59, 585-90		42
886	Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer. 2006 , 12, 4436s-4440s		29
885	Protein kinases as drug targets in cancer. 2006 , 6, 623-34		68
884	EGFR-targeting monoclonal antibodies in head and neck cancer. 2006 , 6, 691-710		30
883	Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. 2006 , 24, 2038-43		508
882	High-throughput mutational analysis of the human cancer genome. 2006 , 7, 597-612		13
881	Cancer Pharmacogenetics: The Move from Pharmacokinetics to Pharmacodynamics. 2006 , 4, 39-46		10
880	gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. 2006 , 6, 197-205		53

879	Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises. 2006 , 6, 271-94	27
878	Editorial. 2006 , 2, 1-1	
877	Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. 2006 , 12, 710-7	104
876	Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. 2006 , 3, e485	242
875	A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. 2006 , 12, 3381-8	101
874	Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model. 2006 , 5, 1754-63	11
873	Syphilis: a forgotten priority. 2006 , 3, e204; author reply e207	4
872	Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. 2006 , 12, 4365s-4371s	42
871	The impact of genomics and proteomics in the clinic: functional genetic polymorphisms and their value in response and toxicity prediction in solid tumours. 2006 , 17 Suppl 10, x263-8	4
870	Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes. 2006 , 36, 523-6	10
869	Potential disease targets for drugs that disrupt protein-- protein interactions of Grb2 and Crk family adaptors. 2006 , 12, 529-48	37
868	Angiogenesis inhibitors: perspectives for medical, surgical and radiation oncology. 2006 , 12, 2623-30	45
867	Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. 2006 , 24, 2659-65	131
866	Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. 2006 , 4, 521-8	119
865	Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. 2006 , 36, 351-6	51
864	Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. 2006 , 12, 3078-84	85
863	MicroRNAs as a potential magic bullet in cancer. 2006 , 2, 73-82	65
862	Mouse models of lung cancer. 2006 , 12, 4396s-4402s	35

861	Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. 2006 , 12, 7222-31	75
860	Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. 2006 , 5, 2051-9	106
859	Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. 2006 , 5, 2676-84	197
858	Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. 2006 , 11, 655-65	42
857	Genetic alterations in signaling pathways in melanoma. 2006 , 12, 2301s-2307s	139
856	Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. 2006 , 24, 5079-90	207
855	Update on epidermal growth factor receptor mutations in non-small cell lung cancer. 2006 , 12, 7232-41	315
854	Tumor dormancy and the role of metastasis suppressor genes in regulating ectopic growth. 2006 , 2, 627-41	22
853	Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. 2006 , 5, 1154-65	79
852	Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. 2006 , 12, 7406-13	17
851	CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. 2006 , 98, 1714-23	93
850	A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. 2006 , 12, 751-8	199
849	Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. 2006 , 12, 43-8	173
848	Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. 2006 , 12, 7117-25	104
847	Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. 2006 , 126, 608-15	130
846	Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. 2006 , 66, 6097-104	155
845	Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. 2006 , 24, 5253-8	163
844	Chemical enhancers of cytokine signaling that suppress microfilament turnover and tumor cell growth. 2006 , 66, 3558-66	9

843	Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. 2006 , 12, 4421s-4425s	57
842	Exercise induced bronchoconstriction in elite athletes: measuring the fall. 2006 , 61, 94-6	14
841	Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. 2007 , 44, 166-72	37
840	EGFR mutation in gefitinib-responsive small-cell lung cancer. 2006 , 17, 1028-9	82
839	Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. 2006 , 24, 4170-6	478
838	Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. 2006 , 12, 4645-51	31
837	Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. 2006 , 12, 839-44	597
836	Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. 2006 , 12, 617-25	77
835	Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study. 2007 , 29, 128-33	11
834	Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. 2006 , 24, 2252-60	122
833	Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. 2006 , 66, 6487-91	121
832	Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. 2006 , 12, 4671-7	56
831	Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. 2006 , 5, 209-18	87
830	Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. 2006 , 98, 580-98	167
829	Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. 2006 , 5, 104-13	55
828	Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. 2006 , 12, 1680-5	136
827	Erlotinib: optimizing therapy with predictors of response?. 2006 , 12, 2961-3	20
826	Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. 2006 , 20, 1496-510	363

825	Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. 2006 , 12, 4416s-4420s	113
824	Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. 2006 , 61, 140-5	102
823	A blood-based test for epidermal growth factor receptor mutations in lung cancer. 2006 , 12, 3875-7	8
822	Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. 2006 , 66, 7854-8	378
821	Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. 2006 , 12, 1647-53	356
820	Gefitinib for epidermal growth factor receptor mutant lung cancers: searching for a weapon of mass destruction. 2006 , 24, 3319-21	7
819	Genetics of Lung Cancer: Current Thinking on Genetic Predisposition to the Disease and Response to Treatment. 2006 , 57-66	
818	Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration. 2006 , 5, 1895-903	12
817	Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. 2006 , 11, 358-73	54
816	Mouse modeling in oncologic preclinical and translational research. 2006 , 12, 5305-11	53
815	Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. 2006 , 24, 1679-88	257
814	Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?. 2006 , 12, 4409s-4415s	44
813	HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. 2007 , 60, 768-72	90
812	Targeted therapies in combination with chemotherapy in non-small cell lung cancer. 2006 , 12, 4451s-4457s	16
811	Epidermal growth factor receptor mutation testing in the care of lung cancer patients. 2006 , 12, 4403s-4408s	68
810	Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. 2006 , 12, 5764-9	526
809	Lung cancer in never-smokers. 2007 , 60, 337-40	32
808	Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC. 2006 , 2, 47-51	6

807	Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA). 2006 , 5, 1610-27	72
806	Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B. 2006 , 66, 10741-9	67
805	Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. 2006 , 3, 50-7; quiz 1 p following 57	102
804	Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. 2006 , 66, 8163-71	315
803	Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. 2006 , 66, 7708-15	34
802	PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. 2006 , 66, 5346-53	58
801	Somatic mutations lead to an oncogenic deletion of met in lung cancer. 2006 , 66, 283-9	364
800	Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. 2006 , 12, 3652-6	54
799	Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. 2006 , 12, 3908-14	479
798	RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. 2006 , 24, 4731-7	286
797	Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. 2006 , 5, 657-64	139
796	Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. 2006 , 12, 2538-44	215
795	Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. 2006 , 66, 5542-8	185
794	The future in diagnosis and staging of lung cancer. Molecular techniques. 2006 , 73, 575-80	9
793	Telomerase activation in a model of lung adenocarcinoma. 2006 , 27, 1175-82	20
792	Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response. 2006 , 12, 7252-60	89
791	Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. 2006 , 24, 2245-51	274
790	Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. 2006 , 24, 4914-21	450

789	SV40 T/t-common polypeptide specifically induces apoptosis in human cancer cells that overexpress HER2/neu. 2006 , 66, 5847-57	8
788	Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. 2006 , 66, 4256-62	47
787	Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. 2006 , 66, 3802-12	51
786	Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. 2006 , 66, 10100-11	291
785	Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. 2006 , 12, 57-61	179
784	Genomic approaches to lung cancer. 2006 , 12, 4384s-4391s	40
783	Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. 2006 , 12, 5659-67	180
782	Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. 2006 , 12, 6494-501	677
781	Lung cancer genetics and pharmacogenomics. 2006 , 115, 298-302	2
780	Pharmacogenomics: Bench to Bedside. 2006 , 4, 431-441	1
779	Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. 2006 , 17 Suppl 2, ii42-45	23
778	A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). 2006 , 17, 1007-13	82
777	Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. 2006 , 17, 1120-7	75
776	Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib. 2006 , 153, 457-66	30
775	Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. 2006 , 24, 4517-20	210
774	Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy. 2006 , 6, 207-27	11
773	Free Flap Head and Neck Reconstruction After Cancer Therapy: Current State of the Art. 2006 , 2, 67-72	
772	The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. 2006 , 12, 4372s-4376s	68

771	Non-small cell lung cancer: second-line and beyond. 2006 , 17 Suppl 10, x97-100	6
770	Molecular diagnosis of a BRAF papillary thyroid carcinoma with multiple chromosome abnormalities and rare adrenal and hypothalamic metastases. 2006 , 16, 1293-302	20
769	Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. 2006 , 12, 7242-51	276
768	Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. 2006 , 103, 6901-6	122
767	Systems Biology: a new hope for drug discovery?. 2006 , 1, 653-61	3
766	The gefitinib-sensitizing mutant epidermal growth factor receptor enables transformation of a mouse fibroblast cell line. 2006 , 25, 246-51	11
765	Target Discovery and Validation Reviews and Protocols. 2006 ,	1
764	Epidermal growth factor receptor inhibition and non-small cell lung cancer. 2006 , 43, 291-323	14
763	Recent developments in the chemotherapeutic options for nonsmall cell lung cancer. 2006 , 6, 1397-410	
762	Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. 2006 , 281, 40183-92	78
761	Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. 2006 , 103, 7817-22	229
760	Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. 2006 , 12, 4103-11	209
759	Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer. 2006 , 4, 971-81	30
758	Current concepts in bronchioloalveolar carcinoma biology. 2006 , 12, 3698-704	39
757	Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. 2006 , 66, 9601-8	174
756	Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. 2006 , 12, 62-9	66
755	Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays. 2006 , 3, 256-68	105
754	Les cancers ovariens. 2006 ,	

753	A new era for bronchioloalveolar carcinoma: current state of the art and recent advances in biologically targeted therapy. 2006 , 6, 1411-9	1
752	Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer. 2006 , 6, 1179-93	30
751	Malignant melanoma: genetics and therapeutics in the genomic era. 2006 , 20, 2149-82	379
750	Molecular imaging in the development of cancer therapeutics. 2006 , 57, 99-118	96
749	Cetuximab in the treatment of head and neck cancer. 2006 , 6, 1539-52	23
748	Molecular targets in melanoma from angiogenesis to apoptosis. 2006 , 12, 2376s-2383s	40
747	Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor. 2006 , 20, 311-3	40
746	Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. 2006 , 66, 6990-7	74
745	Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. 2006 , 103, 2316-21	436
744	Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. 2006 , 66, 3162-8	196
743	Significance of EGFR Protein Expression and Gene Amplification in Non-Small Cell Lung Carcinoma. 2006 , 125, 860-865	98
742	Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. 2006 , 11, 602-11	27
741	Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation. 2006 , 12, 2937-43	13
740	EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. 2006 , 8, 137-44	68
739	Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. 2006 , 66, 4742-9	132
738	Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. 2006 , 12, 3915-21	265
737	Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. 2006 , 24, 1612-9	181
736	Cell Motility in Cancer Invasion and Metastasis. 2006 ,	5

735	Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses. 2007 , 3, 144	182
734	Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 2007 , 12, 325-30	54
733	Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. 2007 , 25, 5777-84	177
732	Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. 2007 , 25, 2164-70	314
731	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. 2007 , 7, 821-36	9
730	Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. 2007 , 67, 2226-38	272
729	Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. 2007 , 13, 2795-803	222
728	Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. 2007 , 25, 3936-44	105
727	Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. 2007 , 6, 2642-51	47
726	Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. 2007 , 13, 1540-51	94
725	Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapies. 2007 , 25, 5155-7	35
724	Targeting HER2 in prostate cancer: where to next?. 2007 , 25, 241-3	39
723	Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. 2007 , 282, 3428-32	88
722	Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. 2007 , 6, 471-83	76
721	The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. 2007 , 13, 1911-25	59
720	Uncommon tumors and exceptional therapies: paradox or paradigm?. 2007 , 6, 1175-9	42
719	Multigene amplification and massively parallel sequencing for cancer mutation discovery. 2007 , 104, 9387-92	143
718	The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. 2007 , 13, 5763-8	71

7 ¹⁷	Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. 2007 , 67, 2325-30	159
7 ¹⁶	Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays. 2007 , 6, 515-23	22
7 ¹⁵	Telomere length and telomerase expression in atypical adenomatous hyperplasia and small bronchioloalveolar carcinoma of the lung. 2007 , 127, 254-62	24
7 ¹⁴	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. 2007 , 104, 20932-7	1395
7 ¹³	Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer. 2007 , 71, 508-18	23
7 ¹²	Systematic analysis of genetic alterations in tumors using Cancer Genome WorkBench (CGWB). 2007 , 17, 1111-7	19
7 ¹¹	Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. 2007 , 13, 6175-81	78
7 ¹⁰	Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. 2007 , 6, 1683-91	234
7 ⁰⁹	Targeting HER proteins in cancer therapy and the role of the non-target HER3. 2007 , 97, 453-7	215
7 ⁰⁸	Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. 2007 , 7, 503-18	27
7 ⁰⁷	CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation. 2007 , 4, 603-7	16
7 ⁰⁶	HER family inhibitors in pancreatic cancer: current status and future directions. 2007 , 11, 337-47	5
7 ⁰⁵	DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. <i>New England Journal of Medicine</i> , 2007 , 356, 800-8	59.2 407
7 ⁰⁴	Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). 2007 , 96, 1047-51	156
7 ⁰³	'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. 2007 , 97, 1560-6	66
7 ⁰²	Unifying electrostatic mechanism for phosphates and sulfates in cell signaling. 2007 , 27, 433-43	20
7 ⁰¹	Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer. 2007 , 7, 415-22	41
7 ⁰⁰	Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. 2007 , 8, 49-66	47

699	Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. 2007 , 13, 2254-60	53
698	BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. 2007 , 4, 1669-79; discussion 1680	376
697	Tyrosine kinase mutations in human cancer. 2007 , 7, 77-84	53
696	Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor. 2007 , 3, 69-77	6
695	Novel multifunctional PHDCA/PEI nano-drug carriers for simultaneous magnetically targeted cancer therapy and diagnosis via magnetic resonance imaging. 2007 , 18, 475105	27
694	Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. 2007 , 67, 5779-88	102
693	Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. 2007 , 67, 5267-74	130
692	Development of an Operational Plan for the Liquid Biopsy External Quality Assessment Program in Korea. 2020 , 42, 91-96	
691	Cardiovascular effects of innovative therapies in lung cancer. 2020 , 154-166	
690	Therapy-induced transdifferentiation promotes glioma growth independent of EGFR signaling.	
689	Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma. 2020 , 164, 127-132	
688	A tyrosine kinase protein interaction map reveals targetable EGFR network oncogenesis in lung cancer.	
687	Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer. 2020 , 96, 266-272	2
686	Current Status of Translational Research in Lung Cancer and Perspectives and Challenges of Academic Translational Research in Japan. 2020 , 60, 305-313	
685	Ascofuranone inhibits epidermal growth factor-induced cell migration by blocking epithelial-mesenchymal transition in lung cancer cells. 2020 , 880, 173199	0
684	EBUS in optimizing non-small cell lung cancer diagnosis and treatment. 2021 , 94, 176-184	2
683	Technical aspects of the use of cytopathological specimens for diagnosis and predictive testing in malignant epithelial neoplasms of the lung. 2021 ,	0
682	Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer. 2021 , 22,	4

- 681 Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer. **2021**, 22, 4
- 680 EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1. **2021**, 4, 1237 5
- 679 Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study. **2021**, 6, 374 1
- 678 Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC. **2021**, 2, 100252 2
- 677 Tumour Content Ratio Matters for Detecting Epidermal Growth Factor Receptor Mutation by Cobas Test in Small Biopsies; a Retrospective Study.
- 676 Introduction to Molecular Targeted Radiosensitizers: Opportunities and Challenges. **2020**, 1-16
- 675 Testing for Driver Oncogenes is Essential for the Optimal Treatment of Advanced Non-small-cell Lung Cancer. **2020**, 66, 403-409
- 674 Coiled coil control of growth factor and inhibitor-dependent EGFR trafficking and degradation. 2
- 673 Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: a preferential benefit for squamous cell carcinoma. **2020**, 55, 66-76 1
- 672 An Overview of Promising Biomarkers in Cancer Screening and Detection. **2020**, 20, 831-852 1
- 671 Druggable driver gene alterations in redefined large cell carcinoma in Chinese patients: an observational study.. **2020**, 9, 7562-7571
- 670 Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy. **2020**, 194-198
- 669 Clinical pharmacogenetics. **2022**, 189-212
- 668 Diagnostic, prognostic, predictive and therapeutic molecular biomarkers in CRC: Understanding the present and foreseeing the future. **2022**, 207-230
- 667 Renal Cancer Including Molecular Characterization. **2020**, 551-559
- 666 Therapy Response Imaging in Thoracic Malignancy. **2020**, 79-97
- 665 Diagnostics and Personalized Medicine. **2020**, 281-304
- 664 Summary and Future Applications of Precision Medicine in Pulmonary, Critical Care, and Sleep Medicine. **2020**, 417-428

- 663 Lessons for Precision Medicine from Lung Cancer. **2020**, 201-223
- 662 Tumour Content Ratio Matters for Detecting Epidermal Growth Factor Receptor Mutation by Cobas Test in Small Biopsies; a Retrospective Study.
- 661 The Pharmacogenomics "Side-effect" of TP53/EGFR in Non-small Cell Lung Cancer Accompanied with Atorvastatin Therapy: A Functional Network Analysis. **2019**, 19, 2060-2071 0
- 660 Tumor Profiling. **2020**, 319-327
- 659 CHAPTER 8:Chemical Probes for Kinases. **2020**, 182-213
- 658 Experience with Large Panel Next-generation Sequencing in Patients with Advanced Solid Cancers at Juntendo University Hospital. **2020**, 66, 392-402
- 657 Triple Mutation Epidermal Growth Factor Receptor (EGFR) Exon 18 (G719S), 20 (T790M) and 21 (L858R) in a Male Patient with Lung Adenocarcinoma: A Case Report. **2020**, 6, 13
- 656 A novel loop-mediated isothermal amplification method for efficient and robust detection of EGFR mutations. **2020**, 56, 743-749 3
- 655 Low-abundance mutations in colorectal cancer patients and healthy adults. **2020**, 12, 808-824
- 654 Biofabrication of 3D tumor models in cancer research. **2020**, 67-90
- 653 Cancfoгенe et maladie cancfеuse. **2020**, 31-35.e1
- 652 CHAPTER 15:Precision Oncology. **2020**, 345-362 0
- 651 Targeting gallbladder cancer: a pathway based perspective. **2020**, 47, 2361-2369 2
- 650 Identification of Epidermal Growth Factor Receptor Tyrosine-Kinase Mutations in Non-small Cell Lung Cancer: Testing Platform Matters. **2020**, 12, e7316
- 649 Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR-tyrosine kinase inhibitor treatment in patients with non-small cell lung cancer from different ethnic groups. **2020**, 19, 3513-3520 1
- 648 Conditionally Reprogrammed Cells and Robotic High-Throughput Screening for Precision Cancer Therapy. **2021**, 11, 761986 0
- 647 Structure-based classification of EGFR mutations informs inhibitor selection for lung cancer therapy. **2021**, 39, 1455-1457
- 646 Quantitative volumetric assessment of the solid portion percentage on CT images to predict ROS1/ALK rearrangements in lung adenocarcinomas. **2020**, 20, 2987-2996 1

- 645 Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC. **2020**, 57, 939-955 1
- 644 Cancer Drug Delivery. 52-95
- 643 Fundamental Aspects of the Cell Cycle and Signal Transduction. **2006**, 207-213
- 642 Technologies in Molecular Biology: Diagnostic Applications. **2006**, 269-284
- 641 Targeting Oncogenes Which Regulate Apoptosis. **2005**, 117-144
- 640 Aspects morphologiques et moléculaires des lésions pré-invasives broncho-pulmonaires : impact sur leur évolutivité. **2005**, 89-110
- 639 Les thérapies ciblées ou le traitement des mécanismes moléculaires de la progression tumorale. **2006**, 515-527
- 638 Die Zukunft der Genetik Zwischen Gentechnik und Genomforschung. **1995**, 763-784
- 637 Pathologic and Molecular Techniques Used in the Diagnosis and Treatment Planning of Sarcomas. **2006**, 13-34
- 636 Molecular Staging of Non-Small-Cell Lung Cancer. **2006**, 159-176 2
- 635 Integration of Biological Therapies in Locally Advanced Non-Small-Cell Lung Cancer. **2006**, 261-270
- 634 Chemoprevention of Lung Cancer. **2006**, 609-626
- 633 Molecular Biology of Lung Cancer. **2006**, 67-80
- 632 Signal transduction inhibitors. **2006**, 185-199
- 631 Dawn of a new era in molecular cancer therapeutics. **2005**, 63, 1-17 1
- 630 Non-Small Cell Lung Carcinoma: EGFR Gene Mutations and Response to Gefitinib. **2008**, 291-306
- 629 Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib. **2008**, 307-316 1
- 628 Non-Small Cell Lung Cancer with Brain Metastasis: Role of Epidermal Growth Factor Receptor Gene Mutation. **2008**, 371-387

- 627 Molecular pathology. 95-118 1
- 626 Cancer Chemotherapy. **2006**, 543-557
- 625 Angiogenesis Inhibitors for the Treatment of Lung Cancer. **2008**, 409-426 0
- 624 The Advancement of Epidermal Growth Factor Receptor Inhibitors in Cancer Therapy. **2007**, 335-357
- 623 Tyrosine Kinase Inhibitors. **2007**, 477-508
- 622 Expression Profiling of Prostate Cancer Progression. **2007**, 247-267
- 621 Somatic Alterations in Prostate Cancer Progression. **2007**, 269-283
- 620 The Cell Cycle. **2008**, 3-32
- 619 Untargeted Use of Targeted Therapy. **2008**, 227-240
- 618 Renal Cell Carcinoma. **2008**, 241-261
- 617 Molecular Targets in Ovarian Cancer and Endometrial Cancer. **2008**, 291-308
- 616 Patient Selection for Rational Development of Novel Anticancer Agents. **2008**, 641-648
- 615 How to Define Treatment Success or Failure if Tumors Do Not Shrink. **2008**, 657-674
- 614 Molecular Targeting of Colorectal Cancer. **2008**, 133-163
- 613 Combining Targeted Therapies. **2008**, 361-381
- 612 Drug Development in Cancer Medicine: Challenges for Targeted Approaches. **2008**, 383-410
- 611 Targeted lung cancer therapy: what have we learned from gefitinib?. **2005**, 2, 1-2
- 610 Targeting the HER Family of Receptors in the Treatment of Advanced Breast Cancer. **2006**, 643-670

609	RNA interference and nonviral targeted gene therapy of experimental brain cancer. 2005 , 2, 139-150	
608	Landmark Studies of Targeted Therapies for Advanced Non-Small Cell Lung Cancer: A Guide for Pulmonologists. 2020 , 16, 5-10	
607	Cancer Epigenomics and Beyond: Advancing the Precision Oncology Paradigm. 2020 , 3, 147-156	
606	Clinical features and mutation status of EGFR, KRAS, BRAF, EML4-ALK and ROS1 between surgical resection samples and non surgical resection samples in lung cancer. 2015 , 7, 875-80	10
605	[A comparison of direct sequencing and ARMS assay performance in EGFR mutation analysis of non-small cell lung cancer patients]. 2014 , 17, 606-11	3
604	Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. 2015 , 3, 81	9
603	TRAIL apoptotic pathway-targeted therapies for NSCLC. 2012 , 1, 155-7	2
602	Cutaneous metastasis as an initial presentation of lung adenocarcinoma with KRAS mutation: a case report and literature review. 2014 , 1, 6	3
601	Renal cell carcinoma and the use of sorafenib. 2006 , 2, 87-98	11
600	The Jeremiah Metzger Lecture: intelligent design of cancer therapy: trials and tribulations. 2007 , 118, 253-61	4
599	Thirty years into the genomics era: tumor viruses led the way. 2006 , 79, 179-85	1
598	The use of EGFR exon 19 and 21 unlabeled DNA probes to screen for activating mutations in non-small cell lung cancer. 2008 , 19, 217-24	10
597	HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer. 2007 , 1, 221-7	16
596	Incorporation of biologic therapies in the management of gastroesophageal cancers. 2007 , 1, S22-9	
595	Cancer as a system failure. 2007 , 5, 10-8	
594	Review of erlotinib in the treatment of advanced non-small cell lung cancer. 2007 , 1, 335-46	22
593	Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab. 2007 , 1, 185-94	4
592	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. 2009 , 3, 215-24	24

591	Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. 2009 , 3, 419-28	29
590	Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. 2009 , 1, 101-14	11
589	Pharmacogenetics: implementing personalized medicine. 2009 , 6, 17-24	28
588	The role of pharmacogenetics and pharmacogenomics in improving translational medicine. 2009 , 6, 13-6	2
587	Lung cancer cytology: potential pitfalls and mimics - a review. 2010 , 3, 367-85	47
586	Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung. 2010 , 2, 309-15	4
585	Bronchioloalveolar neoplasia. 2010 , 4, 97-9	4
584	A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells. 2009 , 15, 213-20	8
583	Mutations in epidermal growth factor receptor gene in esophageal squamous cell carcinoma patients in kashmir- a high incidence area of India. 2008 , 2, 17-25	3
582	Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity. 2008 , 4, 1-13	6
581	Emerging tactical strategies for fighting the war on cancer based on the genetic landscape. 2011 , 3, 251-8	1
580	Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer. 2011 , 36, 263-79	14
579	N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells. 2011 , 1, 823-33	19
578	Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. 2010 , 2, 48-51	184
577	Patient selection in non-small cell lung cancer: Histologic versus molecular subtypes?. 2010 , 2, 189-91	1
576	Current status of immunotherapy for the treatment of lung cancer. 2010 , 2, 237-44	16
575	Targeted therapy: a new approach for the treatment of locally advanced oropharyngeal cancer. 2012 , 4, 82-5	
574	Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. 2010 , 10, 1-48	23

573	Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM. 2012 , 4, 214-6	16
572	A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer. 2012 , 5, 112-8	5
571	The 5 stages of biotechnology management. 2005 , 2, 45-50	
570	Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer. 2013 , 5, 200-11	30
569	Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications. 2010 , 10, 44-51	53
568	Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. 2013 , 5, 481-96	13
567	Infrequent ERBB2 mutations in Chinese patients with non-small cell lung cancer. 2014 , 6, 503-6	1
566	Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. 2014 , 17, 101-14	35
565	EGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysis. 2014 , 7, 1967-78	16
564	Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation. 2011 , 4, 1-35	5
563	Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts. 2014 , 6, S568-80	8
562	ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. 2014 , 12, 429-39	167
561	Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification of lung adenocarcinoma. 2014 , 7, 8039-45	25
560	Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma. 2014 , 26, 705-10	2
559	Detection of EGFR mutation in supernatant, cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing. 2014 , 7, 8813-22	23
558	Expanding options for EGFR targeting in lung cancer. 2012 , 1, 287-8	2
557	Treating acquired resistance to EGFR-tyrosine kinase inhibitors: still a work in progress. 2012 , 1, 149-51	1
556	TKIs in NSCLC: the dawn of a new era?. 2012 , 1, 147-8	

555	Advances on EGFR mutation for lung cancer. 2012 , 1, 5-13	38
554	Apoptotic agents. 2013 , 2, 238-43	3
553	Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy. 2013 , 2, 256-8	16
552	Influence of chemotherapy on EGFR mutation status. 2013 , 2, 442-4	7
551	Does the order of factors affect the product? Lessons learned from the TORCH trial. 2013 , 2, 50-4	
550	MET inhibition in lung cancer. 2013 , 2, 23-39	11
549	10(th) Congress on Lung Cancer-updates on clinical trials: goal. 2014 , 3, 66-9	1
548	Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond. 2013 , 2, 411-4	1
547	Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?-An update incorporating the DELTA trial data. 2015 , 7, 224-6	1
546	Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a decade of progress and hopeful future. 2015 , 7, 217-9	
545	Apoptosis-inducing effects of cetuximab combined with radiotherapy and hypothermia on human nasopharyngeal carcinoma CNE cells. 2015 , 8, 2182-9	7
544	Integrin beta-8 (ITGB8) silencing reverses gefitinib resistance of human hepatic cancer HepG2/G cell line. 2015 , 8, 3063-71	15
543	Prognostic role of p53 and Ki-67 immunohistochemical expression in patients with surgically resected lung adenocarcinoma: a retrospective study. 2015 , 7, 822-33	7
542	Epidermal growth factor receptor mutation analysis in cytological specimens and responsiveness to gefitinib in advanced non-small cell lung cancer patients. 2015 , 27, 294-300	4
541	Somatic mutation in synchronous primary adenocarcinomas of the left lung: a case report. 2015 , 8, 8579-84	
540	Expression pattern of FGFR2, Grb2 and Plc β acts as a novel prognostic marker of recurrence recurrence-free survival in lung adenocarcinoma. 2015 , 5, 3135-48	9
539	Cigarette smoking impairs the response of EGFR-TKIs therapy in lung adenocarcinoma patients by promoting EGFR signaling and epithelial-mesenchymal transition. 2015 , 7, 2026-35	22
538	Phase I study of icotinib, an EGFR tyrosine kinase inhibitor combined with IMRT in nasopharyngeal carcinoma. 2015 , 8, 15675-83	1

537	EGFR kinase-dependent and kinase-independent roles in clear cell renal cell carcinoma. 2016 , 6, 71-83	21
536	Assessment of epidermal growth factor receptor status in glioblastomas. 2013 , 1, 47-52	
535	A perspective on anti-EGFR therapies targeting triple-negative breast cancer. 2016 , 6, 1609-23	115
534	Drug resistance in lung cancer. 2010 , 1, 23-36	54
533	Molecular mechanism underlying the pharmacological interactions of the protein kinase C- β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells. 2017 , 7, 816-830	2
532	The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models. 2017 , 7, 962-972	29
531	Postoperative survival According to the Glasgow Prognostic Score in Patients with Resected Lung Adenocarcinoma. 2016 , 17, 4677-4680	4
530	Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis. 2017 , 18, 107-114	9
529	A novel treatment approach for retinoblastoma by targeting epithelial growth factor receptor expression with a shRNA lentiviral system. 2017 , 20, 739-744	4
528	Leptomeningeal Disease and the Evolving Role of Molecular Targeted Therapy and Immunotherapy. 2017 , 17, 362-378	8
527	Molecular Targets in Non-Small Cell Lung Cancer. 2017 , 17, 388-392	14
526	Assessment of very early response evaluation with F-FDG-PET/CT predicts survival in erlotinib treated NSCLC patients-A comparison of methods. 2018 , 8, 50-61	4
525	Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer. 2016 , 7, 723-735	4
524	Identifying the Causes of Cancer Health Disparities: Biologic and Non Biologic Determinants. 2010 , 8, 101-111	1
523	[Clinical Experience with First-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients with Brain Metastasis]. 2017 , 20, 114-123	
522	[Research Progress of EGFR-TKI Therapy for Patients with Central Nervous System Metastases from Non-small Cell Lung Cancer]. 2016 , 19, 496-500	
521	[Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations]. 2016 , 19, 550-8	2
520	[The Clinical and Molecular Characteristics of Adenocarcinoma Presented by Multi-focal GGO]. 2018 , 21, 163-167	1

- 519 [EGFR and KRAS Gene Mutations in 754 Patients with Resectable Stage I-IIIa Non-small Cell Lung Cancer and Its Clinical Significance]. **2017**, 20, 617-622 3
- 518 [Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer]. **2016**, 19, 679-681
- 517 [Classification and regression tree analysis of clinical patterns that predict survival in 127 Chinese patients with advanced non-small cell lung cancer treated by gefitinib who failed to previous chemotherapy]. **2011**, 14, 699-703
- 516 [Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib ?in Patients with Non-small Cell Lung Cancer]. **2011**, 14, 642-5 3
- 515 [Research Advancement on EGFR Mutation Detection of Cell-free DNA and Tumor Cell in Peripheral Blood of Patients with Non-small Cell Lung Cancer]. **2016**, 19, 766-772
- 514 [Retreatment with epidermal growth factor receptor inhibitor after initial failure in advanced non-small cell lung cancer]. **2011**, 14, 261-5 2
- 513 [The detection methods of EGFR mutations in non-small cell lung cancer]. **2011**, 14, 297-302 0
- 512 [Comparison of EGFR mutation status in paired pre- and post-chemotherapy serum for advanced pulmonary adenocarcinoma]. **2011**, 14, 127-31 3
- 511 [Optimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptor]. **2015**, 18, 110-6
- 510 [EGFR gene mutation statuses in advanced non-small cell lung cancer patients and their influence on effect of gefitinib]. **2012**, 15, 513-20 1
- 509 [Sequence-dependent effect of docetaxel with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975]. **2012**, 15, 127-38 0
- 508 [Discordance of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in non-small cell lung cancer]. **2011**, 14, 518-22 4
- 507 [Classification and regression tree analysis of clinical patterns to predict the survival of patients with advanced non-small cell lung cancer treated with erlotinib]. **2011**, 14, 785-9 0
- 506 [Effectiveness of EGFR-TKIs versus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a meta-analysis]. **2015**, 18, 146-54 0
- 505 [Analyzing the Sensitivity of EGFR-L861Q Mutation to TKIs and A Case Report]. **2015**, 18, 592-8
- 504 [Clinical Experience of Gefitinib in the Treatment of 32 Lung Adenocarcinoma Patients with Brain Metastases]. **2015**, 18, 554-8 1
- 503 [Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor ?Receptor Mutations in Non-small Cell Lung Cancer]. **2015**, 18, 493-9 4
- 502 [Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib]. **2015**, 18, 193-8

- 501 [Clinical Research of EGFR and KRAS Mutation in Fine Needle Aspiration Cytology Specimens of Non-small Cell Lung Carcinoma]. **2015**, 18, 199-205
- 500 [A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China]. **2012**, 15, 332-9 3
- 499 [Detection of epidermal growth factor receptor mutations in non-small cell lung cancer tumor specimens from various ways by denaturing high-performance liquid chromatography]. **2010**, 13, 850-5 1
- 498 [Treatment of advanced NSCLC with unknown EGFR gene status?--TKI or chemotherapy?]. **2014**, 17, 709-14
- 497 [Treatment progress for EGFR wild-type advanced non-small cell lung cancer]. **2014**, 17, 575-80
- 496 [Molecular factors related to gefitinib efficacy in advanced non-small cell lung cancer]. **2010**, 13, 247-53
- 495 [Effects of monoclonal antibody cetuximab on proliferation of non-small cell lung cancer cell lines]. **2010**, 13, 769-72 1
- 494 [Clinical effects for patients with recurrent advanced non-small cell lung cancer treated with icotinib hydrochloride]. **2013**, 16, 240-5 4
- 493 [Clinical significance of ROS1 rearrangements in non-small cell lung cancer]. **2013**, 16, 663-70
- 492 Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes. **2005**, 16, 93-94
- 491 [Progressive patterns of gifitinib treating advanced non-small cell lung cancer after obtained resistance]. **2013**, 16, 510-3
- 490 [Local treatment combined with EGFR-TKIs for advanced non-small cell lung cancer with solitary progression during EGFR-TKI treatment]. **2013**, 16, 514-8 0
- 489 [Development of Precision Medicine in the Surgical Treatment of Lung Cancer]. **2016**, 19, 318-20 0
- 488 [Personalized targeted therapy for lung cancer]. **2013**, 16, C21-34
- 487 [Anatomy, biology and concepts, pertaining to lung cancer stage classification]. **2010**, 13, 1-8 1
- 486 Incense burning smoke sensitizes lung cancer cells to EGFR TKI by inducing AREG expression. **2018**, 8, 2575-2589
- 485 [MRTF-A Regulates the Proliferation and Migration of Non-small Cell Lung Cancer Cells of A549 through HOTAIR]. **2019**, 22, 82-89 1
- 484 Effect of EGFR gene polymorphism on efficacy of chemotherapy combined with targeted therapy for non-small cell lung cancer in Chinese patients. **2019**, 9, 619-627 6

483	Combination of cetuximab with met inhibitor in control of cetuximab-resistant oral squamous cell carcinoma. 2019 , 11, 2370-2381	5
482	Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations. 2019 , 9, 1708-1721	2
481	Impact of age on EGFR mutations in never-smoking female lung adenocarcinoma patients with malignant pleural effusion. 2018 , 11, 2811-2815	
480	UBE2T silencing inhibited non-small cell lung cancer cell proliferation and invasion by suppressing the wnt/Eatenin signaling pathway. 2017 , 10, 9482-9488	11
479	[Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer]. 2020 , 23, 118-126	
478	The emerging role of circulating tumor cells in cancer management. 2020 , 12, 332-342	4
477	Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naïve patients with primary lung adenocarcinoma. 2020 , 13, 525-535	1
476	Intracellular paired agent imaging enables improved evaluation of tyrosine kinase inhibitor target engagement. 2020 , 11219,	
475	A population-based study of outcomes in patients with surgically resected non-small cell lung cancer with anaplastic lymphoma kinase-rearranged mutations: A matched-pair study. 2021 , 14, 11	
474	Immunohistochemical analysis and correlation of cyclooxygenase-2 expression status with clinicopathological parameters in head and neck squamous cell carcinomas: An Indian perspective. 2020 , 24, 583	
473	Evaluation of quantitative modeling methods in whole-body, dynamic [C]-erlotinib PET. 2021 , 11, 143-153	o
472	Immunotherapy in non-small cell lung cancer: Update and new insights. 2021 , 7, 1-21	4
471	Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer. 2021 , 1877, 188645	4
470	The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015. 2021 ,	26
469	Pathology and Cancer Genomic Medicine. 2021 , 61, 887-892	
468	Cinobufagin Is a Selective Anti-Cancer Agent against Tumors with EGFR Amplification and PTEN Deletion.. 2021 , 12, 775602	o
467	First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study. 2021 , 1	o
466	The challenge of targets and drug discovery using large-scale screening approaches in onco-hematology.. 2021 ,	

465	An elderly advanced non-small cell lung cancer patient harboring rare epidermal growth factor receptor mutations L861R benefited from afatinib: A case report. 2021 , 100, e27614	0
464	Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance. 2021 , 10,	2
463	Prognosis of epidermal growth factor receptor-mutated stage I lung adenocarcinoma with radiologically solid features. 2021 ,	0
462	Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model. 2021 ,	0
461	Targeting MERTK and AXL in Mutant Non-Small Cell Lung Cancer. 2021 , 13,	2
460	Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer. 2021 ,	2
459	Reflex testing in non-small cell lung carcinoma using DNA- and RNA-based next-generation sequencing-a single-center experience.. 2021 , 10, 4221-4234	0
458	Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids. 2021 , 12, 7014	0
457	Machine Learning-Based Radiomics in Neuro-Oncology. 2022 , 134, 139-151	1
456	Nicht-kleinzelliges Lungenkarzinom: Wandel und Möglichkeiten der molekularen Diagnostik.	
455	Pharmacogenomics of Anti-Cancer Drugs. 2021 ,	
454	A scRNA-seq Based Prediction Model of EGFR-TKIs Resistance in Patients With Non-Small Cell Lung Adenocarcinoma.	
453	Lung cancer risk in never-smokers: An overview of environmental and genetic factors. 2021 , 33, 548-562	2
452	Subclonal landscape of cancer drives resistance to immune therapy.. 2022 , 30, 100507	0
451	Solid Dispersions of Gefitinib Prepared by Spray Drying with Improved Mucoadhesive and Drug Dissolution Properties.. 2022 , 23, 48	1
450	Potential applications of clickable probes in EGFR activity visualization and prediction of EGFR-TKI therapy response for NSCLC patients.. 2022 , 230, 114100	1
449	Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes.. 2021 , 76, 102080	0
448	Design and synthesis of the novel, selective WZ4002 analogue as EGFR-L858R/T790M tyrosine kinase inhibitors for targeted drug therapy in non-small-cell lung cancer (NSCLC). 2022 , 1254, 132313	2

- 447 Lungenkarzinom: Mehr Optionen für Patienten im fortgeschrittenen Stadium.
- 446 Association between mutant classification and the efficacy of pemetrexed-based chemotherapy in Chinese advanced non-small cell lung cancer patients: a multicenter retrospective study.. **2020**, 9, 6039-6049 ○
- 445 A population-based study of outcomes in patients with surgically resected non-small cell lung cancer with anaplastic lymphoma kinase-rearranged mutations: A matched-pair study. **2020**, 14, 11
- 444 Application of CT radiomics features to predict the EGFR mutation status and therapeutic sensitivity to TKIs of advanced lung adenocarcinoma.. **2020**, 9, 6683-6690 ○
- 443 Targeting Co-Delivery of Doxorubicin and Gefitinib by Biotinylated Au NCs for Overcoming Multidrug Resistance in Imaging-Guided Anticancer Therapy.
- 442 Concordance of Cytological Specimens with Histological Tissue for Detection of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer: A Systematic Review. **2021**, 1-11
- 441 Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.. **2021**, 3
- 440 Accounting for EGFR mutations in epidemiological analyses of non-small cell lung cancers: Examples based on the International Lung Cancer Consortium data.. **2022**,
- 439 Resistor: an algorithm for predicting resistance mutations using Pareto optimization over multistate protein design and mutational signatures. ○
- 438 Usefulness of circulating tumor DNA by targeting human papilloma virus-derived sequences as a biomarker in p16-positive oropharyngeal cancer.. **2022**, 12, 572 ○
- 437 El cáncer de pulmón de células no pequeñas en la era de la medicina de precisión. **2022**, 33, 25-35 ○
- 436 Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors.. **2022**, 27, 5
- 435 Mutations in the helix α of the catalytic domain from the EGFR affect its activity in cervical cancer cell lines.. **2022**, 23, 71
- 434 Tumor-specific imaging probes in preclinical applications and clinical trials. **2022**, 49-138
- 433 Influence Factors of Gefitinib Concentration in Patients with Non-Small Cell Lung Cancer in Clinical Treatment. **2022**, 12, 196-205 ○
- 432 Targeting S100A9-ALDH1A1-retinoic acid signaling to suppress brain relapse in EGFR-mutant lung cancer.. **2022**, 2
- 431 Effects of Different Centrifugation Protocols on the Detection of EGFR Mutations in Plasma Cell-Free DNA.. **2022**, ○
- 430 Bronchoalveolar lavage transcriptome characterise IPF endotypes with prognostic impact.. **2022**, ○

429	Mutation patterns of epidermal growth factor receptor gene in non-small cell lung cancer among Egyptian patients. 2022 , 9, 77-90	0
428	Effects of EGFR gene mutation on stage 3A lung adenocarcinomas in the clinical decision-making process for mediastinal invasive staging. 2022 , 9, 44-49	
427	Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.. 2022 , JCO2101626r8	
426	Real-World Analysis of Off-Label Use of Molecularly Targeted Therapy in a Large Academic Medical Center Cohort.. 2022 , 6, e2100232	1
425	Chemotherapeutic potential of hesperetin for cancer treatment, with mechanistic insights: A comprehensive review.. 2022 , 8, e08815	7
424	First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study.. 2022 ,	0
423	Biomarkers in Pulmonary Carcinomas. 2022 , 99-128	0
422	Discovery of a Series of 1,2,3-Triazole-Containing Erlotinib Derivatives With Potent Anti-Tumor Activities Against Non-Small Cell Lung Cancer.. 2021 , 9, 789030	2
421	Extracellular vesicles released by non-small cell lung cancer cells drive invasion and permeability in non-tumorigenic lung epithelial cells.. 2022 , 12, 972	0
420	Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma.. 2022 , 14,	0
419	Integration of heterogeneous biological data in multiscale mechanistic model calibration: application to lung adenocarcinoma.	1
418	Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions.. 2022 ,	0
417	Loss of TET reprograms Wnt signaling through impaired demethylation to promote lung cancer development.. 2022 , 119,	1
416	Probing altered enzyme activity in the biochemical characterization of cancer.. 2022 ,	
415	Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. 2021 ,	0
414	New trend in ligand-induced EGFR trafficking: A dual-mode clathrin-mediated endocytosis model.. 2022 , 255, 104503	1
413	Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.. 2022 , 120, 105605	1
412	Prospects of beneficial microbes as a natural resource for sustainable legumes production under changing climate. 2022 , 29-56	0

411	Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies.. 2022 , 12, 804212	1
410	Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer.. 2022 , 23,	0
409	Liquid Biopsy, Diagnostic Imaging, and Future Synergies.. 2022 , 19, 336-343	1
408	Deciphering the Mechanism of Binding Selectivity of Chlorofluoroacetamide-Based Covalent Inhibitors toward L858R/T790M Resistance Mutation.. 2022 ,	1
407	EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors.. 2022 , 1	1
406	Current Therapy and Development of Therapeutic Agents for Lung Cancer. 2022 , 100015	1
405	Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer.. 2021 , 10,	0
404	Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.. 2021 ,	10
403	Contemporary Molecular Analyses of Malignant Tumors for Precision Treatment and the Implication in Oral Squamous Cell Carcinoma.. 2021 , 12,	1
402	A Case of Metastatic Non-small Cell Lung Adenocarcinoma and Metachronous Primary Hepatocellular Carcinoma.. 2021 , 13, e20185	1
401	Neuro-oncology in a nutshell. 2004 , 70, 1-2	
400	Multi-omics analysis identifies distinct subtypes with clinical relevance in lung adenocarcinoma harboring /.. 2022 , 13, 1512-1522	
399	Molecular Imaging Precision Medicine. 2022 , 79-92	
398	Neurological complications of lung cancer. 2022 , 243-276	
397	Patient-Derived In Vitro and In Vivo Models of Cancer.. 2022 , 1361, 215-233	0
396	Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial.. 2022 , 21, 15347354221086663	0
395	Biology and pathophysiology of central nervous system metastases. 2022 , 55-78	
394	Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis.. 2022 , 17, 153	0

393	Concurrent lung adenocarcinoma and bladder diffuse large B-cell lymphoma: a case report and literature review.. 2022 , 50, 3000605221081672	1
392	Two Unusual Mutations in the Epidermal Growth Factor Receptor Gene in a Patient With Lung Adenocarcinoma.. 2022 , 14, e22372	1
391	Machine Learning-Assisted Dual-Marker Detection in Serum Small Extracellular Vesicles for the Diagnosis and Prognosis Prediction of Non-Small Cell Lung Cancer.. 2022 , 12,	0
390	Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers.. 2022 , 21, 61	0
389	A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma.. 2022 , 11, 238-249	0
388	An engineered abcb4 expression model reveals the central role of NF- κ B in the regulation of drug resistance in zebrafish.. 2022 ,	1
387	MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis.. 2022 , 14,	0
386	Multiplex Droplet Digital PCR Assay for Detection of and Genes Amplification in Non-Small Cell Lung Cancer.. 2022 , 14,	0
385	Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors.. 2022 , 14,	0
384	In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer.	
383	Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERR α -expression.. 2022 , 21, 77	3
382	Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy.. 2022 , 14,	0
381	Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells.. 2022 , 17, e0264717	2
380	Pan-cancer analysis reveals sex-specific signatures in the tumor microenvironment.. 2022 ,	1
379	The Frequency of Epidermal Growth Factor Receptor (EGFR) Mutation in Patients with Lung Adenocarcinoma Referred to a Lung Diseases Hospital; A Cross-Sectional Study from Iran.. 2022 , 17, 159-165	
378	Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer.. 2022 , 12, 869672	3
377	Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation. 2022 , 2022,	
376	Targeted Therapies for Perihilar Cholangiocarcinoma.. 2022 , 14,	0

375	Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer.	0
374	A review on the genetic polymorphisms and susceptibility of cancer patients in Bangladesh.. 2022 , 1	1
373	Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody.. 2022 , 23, 12	0
372	Mutation-Harboring Lung Cancer Cells Produce CLEC11A with Endothelial Trophic and Tumor-Promoting Activities.. 2022 , 14,	0
371	Custom multi-tumor next-generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three-year clinical use.. 2022 , 49,	
370	MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells.. 2022 , 20, 27	0
369	NELL-1 in Genome-Wide Association Studies across Human Disease. 2021 ,	0
368	Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer.. 2022 , 13, 1667	5
367	First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials.. 2022 ,	0
366	Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.. 2022 ,	4
365	Regulation of a Novel Splice Variant of Early Growth Response 4 (EGR4-S) by HER+ Signalling and HSF1 in Breast Cancer.. 2022 , 14,	
364	In Silico and In Vitro Evaluations of Fluorophoric Thiazolo-[2,3-b]quinazolinones as Anti-cancer Agents Targeting EGFR-TKD.. 2022 , 1	
363	An overview of the crosstalk between YAP and cGAS-STING signaling in non-small cell lung cancer: it takes two to tango.. 2022 , 1	0
362	The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor.. 2022 , 15,	0
361	Establishment and Optimization of Radiomics Algorithms for Prediction of KRAS Gene Mutation by Integration of NSCLC Gene Mutation Mutual Exclusion Information.. 2022 , 13, 862581	
360	Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers.. 2022 , 85, 409-413	0
359	Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.. 2022 , 166, 242-249	
358	Construction of a Two-Gene Immunogenomic-Related Prognostic Signature in Lung Squamous Cell Carcinoma.. 2022 , 9, 867494	

357	Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer. 2021 , 21, 1322	1
356	BIX01294 inhibits EGFR signaling in EGFR-mutant lung adenocarcinoma cells through a BCKDHA-mediated reduction in the EGFR level. 2021 ,	1
355	Correlation of epidermal growth factor receptor mutation status and PD-L1 expression with [18F]FDG PET using volume-based parameters in non-small cell lung cancer.. 2021 , 43,	0
354	Harnessing Reversed Allosteric Communication: A Novel Strategy for Allosteric Drug Discovery. 2021 ,	5
353	Prediction of high-risk liver cancer patients from their mutation profile: Benchmarking of mutation calling techniques.	
352	Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.. 2021 , 2, 692-729	2
351	Limited-Stage Small-Cell Lung Cancer: Current Progress and the Next Frontier. 2021 , 1, 317-333	
350	The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management.. 2021 , 21, 675	1
349	EGFR-Dependent Extracellular Matrix Protein Interactions Might Light a Candle in Cell Behavior of Non-Small Cell Lung Cancer.. 2021 , 11, 766659	2
348	Amivantamab for the treatment of exon 20 insertion mutant non-small cell lung cancer.. 2021 , 1-14	1
347	The emergence of cancer genomics in diagnosis and precision medicine.. 2021 , 2, 1263-1264	1
346	Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists.. 2021 ,	2
345	C1632 suppresses the migration and proliferation of non-small-cell lung cancer cells involving LIN28 and FGFR1 pathway.. 2021 ,	1
344	Basic Understandings of EGFR-mutated Lung Cancer and Its Clinical Applications. 2021 , 61, 911-918	
343	Lung squamous cell carcinoma with rare epidermal growth factor receptor mutation G719X: a case report and literature review.. 2021 , 9, 1805	2
342	Recent Advances in Ovarian Cancer Treatment. 2022 , 81, 23-28	
341	Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities.. 2022 , 82, 1589-1602	0
340	A Six-Gene Prognostic and Predictive Radiotherapy-Based Signature for Early and Locally Advanced Stages in Non-Small-Cell Lung Cancer.. 2022 , 14,	1

339	Resistance is futile with fourth-generation EGFR inhibitors.. 2022,	0
338	Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC.. 2022, 12, 6367	1
337	Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.. 2022, 82, 649	2
336	A Hypoxia-Related Signature for Predicting Prognosis, Cellular Processes, Immune Microenvironment and Targeted Compounds in Lung Squamous Cell Carcinoma.. 2022, 15, 3991-4006	
335	EGFR signaling pathway as therapeutic target in human cancers.. 2022,	1
334	Analysis to determine the effect of mutations on binding to small chemical molecules.. 2022, 2240003	
333	Osimertinib-Centered Therapy Against Uncommon Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer- A Mini Review.. 2022, 12, 834585	1
332	A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and F-FDG Metabolic Activity in Non-Small Cell Lung Cancer.. 2022, 12, 780186	1
331	Targeting EGFR, RSK1, RAF1, PARP2 and LIN28B for several cancer type therapies with newly synthesized pyrazole derivatives via a computational study.. 2022, 1-25	1
330	The Ascension of Targeted Covalent Inhibitors.. 2022,	3
329	Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment.. 2022, 237, 114381	0
328	Deregulated signaling networks in lung cancer. 421-442	
327	Cancer pharmacogenomics: challenges, promises, and its application to cancer drug discovery. 499-517	
326	Table_1.DOCX. 2020,	
325	Data_Sheet_1.PDF. 2019,	
324	Data_Sheet_1.pdf. 2020,	
323	Data_Sheet_1.PDF. 2020,	
322	Data_Sheet_2.xlsx. 2020,	

321 Data_Sheet_3.pdf. **2020,**

320 Data_Sheet_1.docx. **2018,**

319 Table_1.xlsx. **2020,**

318 Table_10.docx. **2020,**

317 Table_2.xlsx. **2020,**

316 Table_3.xlsx. **2020,**

315 Table_4.xlsx. **2020,**

314 Table_5.xlsx. **2020,**

313 Table_6.xlsx. **2020,**

312 Table_7.xlsx. **2020,**

311 Table_8.xlsx. **2020,**

310 Table_9.xlsx. **2020,**

309 Image_1.JPEG. **2020,**

308 Image_2.JPEG. **2020,**

307 Data_Sheet_1.pdf. **2018,**

306 Data_Sheet_1.XLSX. **2020,**

305 Data_Sheet_1.docx. **2020,**

304 Presentation_1.pdf. **2018,**

303 Data_Sheet_1.docx. **2018,**

302 Data_Sheet_1.XLSX. **2018,**

301 Presentation_1.PDF. **2018,**

300 Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor. **2005**, 11, 397-405

34

299 [Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer ?with Epidermal Growth Factor Receptor Gene Mutation].. **2022**, 25, 183-192

298 Immunohistochemical analysis and correlation of cyclooxygenase-2 expression status with clinicopathological parameters in head and neck squamous cell carcinomas: An Indian perspective. **2020**, 24, 583

0

297 Low expression of miR-27b in serum exosomes of non-small cell lung cancer facilitates its progression by affecting EGFR.. **2022**, 17, 816-825

296 Trends of Biogenic Nanoparticles in Lung Cancer Theranostics. **2022**, 301-321

295 Histologic and Genotypic Characterization of Lung Cancer in the Inuit Population of the Eastern Canadian Arctic. **2022**, 29, 3171-3186

1

294 Overcoming Cancer Drug Resistance Utilizing PROTAC Technology.. **2022**, 10, 872729

0

293 Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib.. **2022**, 12, 7002

0

292 Translational research: A patient-centered approach to bridge the valley of death.. **2022**,

0

291 Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies.. **2022**, 15, 479-495

1

290 Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration.. **2022**, 7, 157

0

289 Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.. **2022**,

2

288 The translational challenges of precision oncology.. **2022**,

3

287 Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer.. **2022**, 17, e0267362

0

286 Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors.. **2022**, 14,

0

285	Management of Non-Small Cell Lung Cancer: Updates from the European Lung Cancer Congress 2022.. 2022 , 1-27	
284	CPI Adult Cancer Imaging Special Edition Module. 2019 ,	
283	Pleural, Pericardial, and Peritoneal Fluids. 2014 , 127-153	2
282	Targeting ErbB receptor signaling: A pan-ErbB approach to cancer. 2004 , 3, 1335-1342	17
281	Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer.. 2022 ,	0
280	Altered splicing of ATG16-L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non-small cell lung cancer.. 2022 ,	0
279	EGFRC797S mutation and fourth-generation EGFR tyrosine kinase inhibitors. 2022 , 689-709	
278	Biomarkers in Cancer Survival and Drug Resistance. 2022 , 177-200	
277	The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer.	
276	Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer. 2022 , 14, 2613	0
275	Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients.	0
274	Prediction of risk-associated genes and high-risk liver cancer patients from their mutation profile: Benchmarking of mutation calling techniques.	0
273	Randomized phase II study of osimertinib plus bevacizumab versus osimertinib for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations; WJOG9717L study. 2022 ,	5
272	Recognition of BRAF by CDC37 and Reevaluation of the Activation mechanism for the Class 2 BRAF-L597R mutant.	1
271	HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature. 2022 , 29, 3748-3758	0
270	The potential of polygenic scores to improve cost and efficiency of clinical trials. 2022 , 13,	0
269	Perioperative targeted therapy for oncogene-driven NSCLC. 2022 ,	1
268	Targeting Co-delivery of doxorubicin and gefitinib by Biotinylated Au NCs for Overcoming Multidrug Resistance in Imaging-guided Anticancer Therapy. 2022 , 112608	0

267	Chemotherapeutics activities of dietary phytoestrogens against prostate cancer: From observational to clinical studies. 2022 , 28,	0
266	Characteristics of Women with Lung Adenocarcinoma in the World Trade Center Environmental Health Center. 2022 , 19, 7618	0
265	Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare Mutation: Insights from Molecular Simulations. 2022 , 27, 3844	0
264	NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease. 2022 , 23, 6748	1
263	MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.	1
262	Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer.	1
261	S645C Point Mutation Suppresses Degradation of EGFR to Promote Progression of Glioblastoma. 12,	
260	Identification and robust estimation of swapped direct and indirect effects: Mediation analysis with unmeasured mediator-outcome confounding and intermediate confounding.	0
259	High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: results from the phase 2 multicenter POSITION20 trial. 2022 ,	3
258	PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. 2022 , 12,	1
257	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.	9
256	Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Alectinib in Chinese Patients With Lung Cancer. 13,	0
255	Integrated screens uncover a cell surface tumor suppressor gene KIRREL involved in Hippo pathway. 2022 , 119,	0
254	Expanded Application of a Photoaffinity Probe to Study Epidermal Growth Factor Receptor Tyrosine Kinase with Functional Activity.	
253	Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in NonSmall Cell Lung Cancer. 13,	0
252	Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future. 12,	1
251	EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment. 2022 , 23, 6489	1
250	Folic acid-mediated MSNs@Ag@Geb multifunctional nanocomposite heterogeneous platform for combined therapy of non-small cell lung cancer. 2022 , 217, 112639	0

- 249 Aberrant Epidermal Growth Factor Receptor Signaling and Enhanced Sensitivity to EGFR Inhibitors in Lung Cancer. **2005**, 65, 226-235 93
- 248 Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. **2005**, 4, 101-112 46
- 247 EGFR, NF- κ B and noncoding RNAs in precision medicine. **2022**,
- 246 Synthetic Lethality and Lung Cancer. **2022**, 51-62
- 245 Recognition of BRAF by CDC37 and Re-Evaluation of the Activation Mechanism for the Class 2 BRAF-L597R Mutant. **2022**, 12, 905
- 244 Differences in actionable genomic alterations between brain metastases and non-brain metastases in patients with non-small cell lung cancer. **2022**, 61,
- 243 Fbxo45-mediated NP-STEP 46 degradation via K6-linked ubiquitination sustains ERK activity in lung cancer. 0
- 242 Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients.
- 241 Neuronal survival factor VGF promotes chemoresistance and predicts poor prognosis in lung cancers with neuroendocrine feature.
- 240 A rare case of Exon 19 deletion transforming to Exon 20 insertion in a case of adenocarcinoma of lung. 1-4 0
- 239 The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer. **2022**, 13,
- 238 Integration of Heterogeneous Biological Data in Multiscale Mechanistic Model Calibration: Application to Lung Adenocarcinoma. **2022**, 70,
- 237 Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3K β -specific inhibitors and ATP. **2022**, 99, 107726 0
- 236 Highly sensitive detection of EGFR L858R mutation at the mRNA level. **2022**, 654, 114799
- 235 Novel Prognostic Value of Nuclear Epidermal Growth Factor Receptor in Breast Cancer. **2005**, 65, 338-348 66
- 234 Cellular Targets of Gefitinib. **2005**, 65, 379-382 61
- 233 The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non-Small Cell Lung Cancers. **2005**, 11, 1167-1173 87
- 232 A Functional Common Polymorphism in a Sp1 Recognition Site of the Epidermal Growth Factor Receptor Gene Promoter. **2005**, 65, 46-53 33

- 231 Novel peptide ligands for integrin $\alpha 5 \beta 1$ overexpressed in cancer cells. **2004**, 3, 1329-1334 7
- 230 Targeted Therapy in Early Stage Non-small Cell Lung Cancer. 1
- 229 Two Distinct Primary EGFR-Mutated Lung Adenocarcinoma Within the Same Patient: A Case Report.
- 228 Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients. 13, 0
- 227 Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer. **2022**, 119, 1
- 226 Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC. **2022**, 109, 102438 1
- 225 EGFR T790M Site-Mutated Non-Small Cell Lung Cancer Drug Resistance Mechanism and Comprehensive Treatment after Drug Resistance. **2022**, 12, 6872-6881
- 224 Lazertinib: on the Way to Its Throne. **2022**, 63, 799 0
- 223 The Therapy of Osimertinib for EGFR Mutation Non-small Cell Lung Cancer. 6, 219-229
- 222 CD109 Is a Critical Determinant of EGFR Expression and Signaling, and Tumorigenicity in Squamous Cell Carcinoma Cells. **2022**, 14, 3672
- 221 First person profile: Thomas Lynch Jr, MD. **2022**, 128,
- 220 Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report. **2022**, 101, e30080
- 219 Cancer: Immunology and Immunotherapy. **2022**, 159-164
- 218 Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on BRAF: Case Series and Literature Review of Treatment. **2022**, 0
- 217 Participation in phase 1 trials for patients with cancer. **2022**, 400, 473-475
- 216 Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma: a multi-institutional retrospective study.
- 215 Heat shock protein 90 inhibitor 17-AAG down-regulates thymidine phosphorylase expression and potentiates the cytotoxic effect of tamoxifen and erlotinib in human lung squamous carcinoma cells. **2022**, 115207
- 214 Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. **2022**, 1

213	Efficacy and safety of EGFR-TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations.	1
212	Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece.	
211	Combi-seq for multiplexed transcriptome-based profiling of drug combinations using deterministic barcoding in single-cell droplets. 2022 , 13,	1
210	EGFR-mutant NSCLC: monitoring the molecular evolution of tumors in 2022.	0
209	Identification of Lethal Inhibitors and Inhibitor Combinations for Mono-Driver versus Multi-Driver Triple-Negative Breast Cancer Cells. 2022 , 14, 4027	
208	Panel Sequencing for Targeted Therapy Selection in Solid Tumors. 2022 ,	
207	Clinical Validation of Companion Diagnostics for the Selection of Patients with NonSmall Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab. 2022 ,	0
206	Advances in covalent drug discovery.	9
205	Label-free visualization of cellular response to molecularly targeted agents using multiplex CARS and THG (coherent anti-Stokes Raman scattering and third harmonic generation) microscopy.	
204	Impact of LncRNA GAS5 Genetic Variants and the Epidermal Growth Factor Receptor Phenotypes on the Clinicopathological Characteristics of Lung Adenocarcinoma Patients. 2022 , 19, 9971	
203	PELP1 is overexpressed in lung cancer and promotes tumor cell malignancy and resistance to tyrosine kinase inhibitor drug. 2022 , 237, 154065	0
202	Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells. 2022 , 626, 156-166	
201	Epidermal Growth Factor Receptor Gene Polymorphisms Predict Pelvic Recurrence in Patients with Rectal Cancer Treated with Chemoradiation. 2005 , 11, 600-605	13
200	The Evolution of Antibodies into Versatile Tumor-Targeting Agents. 2005 , 11, 129-138	7
199	Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer. 2022 , 28, 331-338	0
198	Elevated phosphorylation of EGFR in NSCLC due to mutations in PTPRH. 2022 , 18, e1010362	2
197	Clinical Laboratory Results as Prognosis Marker in Advanced Stage Non-small Cell Lung Cancer (NSCLC) in Indonesia. 2022 ,	0
196	Control of cell metabolism by the epidermal growth factor receptor. 2022 , 1869, 119359	1

195	Understanding the Molecular Kinetics in NSCLC Through Computational Method. 2022 , 129-163	0
194	Therapeutic Schedule of EGFR Mutation in Non-Small Cell Lung Cancer and Review of Health Insurance Policy. 2022 , 12, 174-183	0
193	EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway: A nationwide retrospective cohort study. 2022 , 33, 100636	0
192	Targeted Therapies in Non-small Cell Lung Cancer. 2022 ,	1
191	QuinolineHydrazone hybrids as dual mutant EGFR inhibitors with promising metallic nanoparticle loading: rationalized design, synthesis, biological investigation and computational studies. 2022 , 46, 18207-18232	1
190	Genomic Alterations in Lung Cancer. 2022 ,	0
189	Substanzen gegen molekulare Zielstrukturen. 2022 , 1-14	0
188	The mechanism of radiotherapy for lung adenocarcinoma in promoting protein SIRT6-mediated deacetylation of RBBP8 to enhance the sensitivity of targeted therapy. 2022 , 36, 039463202211307	0
187	On the way for the best imaging features from CT images to predict EGFR Mutation Status in Lung Cancer. 2022 ,	0
186	Clinical trial design in the era of precision medicine. 2022 , 14,	3
185	A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report. 2022 , 101, e30269	0
184	Development and characterization of reference materials for EGFR, KRAS, NRAS, BRAF, PIK3CA, ALK, and MET genetic testing. 2022 , 1-11	0
183	Effect of thoracic radiotherapy dose on the prognosis of advanced lung adenocarcinoma harboring EGFR mutations. 2022 , 22,	0
182	Can EGFR be a therapeutic target in breast cancer?. 2022 , 1877, 188789	1
181	Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC. 2022 , 12, 2360	0
180	Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer. 2022 , 100406	0
179	EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy.	0
178	Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. 2022 , 7,	1

- 177 Genetic alterations shaping tumor response to anti-EGFR therapies. **2022**, 64, 100863 ○
- 176 Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer. **2022**, 11, 2871 1
- 175 A perspective study on the RTK, PI3K, B-Raf, CDK and the multi-protein targeting in medicinal chemistry. ○
- 174 Minimal residual disease in EGFR-mutant non-small-cell lung cancer. 12, ○
- 173 Identification of Activating Mutations in the Transmembrane and Extracellular Domains of EGFR. **2022**, 61, 2049-2062 ○
- 172 Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations. **2022**, 31, 1647-1662 ○
- 171 Applications of CRISPR/Cas technology against drug-resistant lung cancers: an update. ○
- 170 Thyroid Dysfunction in Non-Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Meta-Analysis. ○
- 169 Preoperative MRI -Based Radiomics of Brain Metastasis to Assess T790M Resistance Mutation After EGFR-TKI Treatment in NSCLC. ○
- 168 Role of intratumoral and peritumoral CT radiomics for the prediction of EGFR gene mutation in primary lung cancer. ○
- 167 Evolution of precision oncology-guided treatment paradigms. ○
- 166 Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs. **2022**, 23, 11353 ○
- 165 The Management of Oligometastases in Non-small Cell Lung Cancer [Is Stereotactic Ablative Radiotherapy now Standard of Care?]. **2022**, ○
- 164 Two non-small cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor receptor (EGFR) G719X and L861Q mutations benefited from aumolertinib: two cases report and review of the literature. **2022**, 8, e10407 ○
- 163 EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer is Associated with a High Incidence of Brain Metastasis. ○
- 162 Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. **2022**, 7, ○
- 161 Editorial: Translating clinical genomics and health informatics into precision oncology. 13, ○
- 160 Discovery of a potent EGFR and ALK dual mutation inhibitor containing N-(3-((4-((2-(cyclopropylsulfinyl)phenyl)amino)pyrimidin-2-yl)amino) phenyl)acrylamide scaffold. **2022**, 106188 1

159	Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations.	0
158	Targeted therapy in oncology. 2022 , 222-228	0
157	Functional genomics of complex cancer genomes. 2022 , 13,	0
156	A case report: Response to Osimertinib in non-small cell lung cancer patient with uncommon EGFR mutation. 2022 , 8, 100188	0
155	Nanoencapsulation of tyrosine kinase inhibitors for oncological therapeutics. 2022 , 251-267	0
154	Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules.	0
153	Research Trends and Emerging Hotspots of Lung Cancer Surgery during 2012-2021: A 10-Year Bibliometric and Network Analysis. 2022 , 2022, 1-10	0
152	PIK3CA mutations associated with a poor postoperative prognosis in patients with pulmonary pleomorphic carcinoma: a retrospective cohort study. 2022 , 22,	0
151	UNcommon EGFR mutations: International Case series on efficacy of osimertinib in Real-life practice in first line setting (UNICORN). 2022 ,	1
150	New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer. 2022 , 23, 1626-1644	1
149	Research on the influence of APOBEC family on the occurrence, diagnosis, and treatment of various tumors.	0
148	Algorithme thérapeutique des cancers bronchiques non ^petites cellules tendus avec mutation de EGFR. 2022 , 14, 2S189-2S208	0
147	Molecular Biology, Genetics, and Translational Models of Human Cancer. 1-34	0
146	Cancer Genomics and Evolution. 1-30	0
145	Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing. 2022 , 12, 1684	0
144	Novel EGFR-Mutant Mouse Models of Lung Adenocarcinoma Reveal Adaptive Immunity Requirement for Durable Osimertinib Response.	0
143	A Detouring Experience Not Recommended: Lessons Learned from PF00299804. 2022 , 82, 3662-3664	0
142	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. 2022 , 15,	1

141	Oncogène pulmonaire et bases biologiques des traitements ciblés. 2022 , 14, 2S16-2S29	0
140	State of the Art: onkogen alteriertes nichtkleinzelliges Lungenkarzinom im Stadium IV.	0
139	Cancer Metabolism. 1-14	0
138	Precision Medicine in Oncology Drug Development. 1-15	0
137	Aberrant Signaling Pathways in Cancer. 1-10	0
136	Clinical cancer immunotherapy: Current progress and prospects. 13,	2
135	Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures. 2022 , 13, 830-843.e3	0
134	MYC and therapy resistance in cancer: risks and opportunities. 2022 , 16, 3828-3854	0
133	Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches. 2022 , 12, 1651	0
132	Editorial for Preoperative MRI -Based Radiomics of Brain Metastasis to Assess T790M Resistance Mutation After EGFR-TKI Treatment in NSCLC □	0
131	Principles of Medical Oncology. 1-13	0
130	A Beclin 1-targeting stapled peptide synergizes with erlotinib to potently inhibit proliferation of non-small-cell lung cancer cells. 2022 , 636, 125-131	1
129	AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models. 2022 , 156, 113942	0
128	Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors. 2022 , 244, 114856	0
127	Translational proteomics and phosphoproteomics: Tissue to extracellular vesicles. 2022 ,	0
126	Improved Survival of Advanced Lung Cancer in Singapore Over the Past Decade. 2017 , 46, 333-338	3
125	The Latest Information on Chemotherapy for Patients with Advanced Lung Cancer. 2021 , 110, 2441-2448	0
124	Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448).	0

- 123 Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation. 12, ○
- 122 Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations. **2022**, 13, ○
- 121 Analyses of P16INK4a gene promoter methylation relative to molecular, demographic and clinical parameters characteristics in non-small cell lung cancer patients: A pilot study. ○
- 120 EGFR Tyrosine Kinase Inhibitor Efficacy in Older Adult Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review. **2022**, 58, 1645 ○
- 119 Changes in survival of patients with non-small cell lung cancer in Japan: an interrupted time series study. ○
- 118 New splice variants of VEGF as relevant targets for the treatment of renal cell carcinoma. ○
- 117 The solvent chosen for the manufacturing of electrospun polycaprolactone scaffolds influences cell behavior of lung cancer cells. **2022**, 12, ○
- 116 A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations. **2022**, 13, ○
- 115 Biomarkers in the management of lung cancer: changing the practice of thoracic oncology. **2022**, ○
- 114 Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer. 12, ○
- 113 Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review. **2022**, 7, 100605 ○
- 112 Local Therapy for Oligometastatic Disease: Part Before the Horse?. **2022**, 114, 836-839 ○
- 111 Early Application of Next-Generation Sequencing Identifies Pancreatic Mass as Metastasis From an EGFR-Mutated Lung Adenocarcinoma. **2022**, 1-6 ○
- 110 Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer. **2023**, 80, 129084 ○
- 109 Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agents. **2022**, 153-172 ○
- 108 Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer. **2022**, 14, 175883592211440 ○
- 107 Multi-omics analysis identifies drivers of protein phosphorylation. ○
- 106 Allosteric activation of preformed EGF receptor dimers by a single ligand binding event. 13, ○

- 105 Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study. **2022**, 22, ○
- 104 A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation. ○
- 103 Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan. ○
- 102 Database of recurrent mutations (DORM), a web tool to browse recurrent mutations in cancers. ○
- 101 Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients. ○
- 100 Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS). ○
- 99 PROTAC therapy as a new targeted therapy for lung cancer. **2022**, ○
- 98 Leukocyte Depletion and Size-Based Enrichment of Circulating Tumor Cells Using a Pressure-Sensing Microfiltration Device. ○
- 97 Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040). **2022**, 22, ○
- 96 Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with EGFR polymorphisms: A systematic review and meta-analysis. **2022**, 25, ○
- 95 An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies. **2023**, 80, ○
- 94 A narrative review of cancer molecular diagnostics: past, present, and future. Publish Ahead of Print, ○
- 93 Current status and challenges of immunotherapy in ALK rearranged NSCLC. 12, ○
- 92 From targeted therapy to a novel way: Immunogenic cell death in lung cancer. 9, ○
- 91 Clinical case of long-term disease control in a patient with <i>EGFR</i>-positive non-small cell lung cancer. **2022**, 154-159 ○
- 90 Clinical impact of histologic type on survival and recurrence in patients with surgically resected stage II and III non-small cell lung cancer. **2022**, ○
- 89 Computational Prediction of Resistance Induced Alanine-Mutation in ATP Site of Epidermal Growth Factor Receptor. **2022**, 23, 15828 ○
- 88 Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. **2022**, 3, ○

87	FBP1 induced by Eelemene enhances the sensitivity of gefitinib in lung cancer.	0
86	Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer. 2023 , 15, 504	1
85	Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response. 2023 , 216062	0
84	LncRNA AFAP1-AS1 Induces Gefitinib Resistance of Lung Adenocarcinoma Through the miR-653-5p/AGR2 Axis. Volume 19, 1-13	0
83	First-, Second-, and Third-Generation Radiolabeled Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Positron Emission Tomography: State of the Art, a Systematic Review.	0
82	Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer. 2023 , 13, 167	1
81	Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins. Volume 15, 11-24	0
80	Histone deacetylase inhibitors as sanguine epitherapeutics against the deadliest lung cancer. 2023 ,	0
79	Targeting EGFR and Monitoring Tumorigenesis of Human Lung Cancer Cells In Vitro and In Vivo Using Nanodiamond-Conjugated Specific EGFR Antibody. 2023 , 15, 111	0
78	Interpretation of Lung Cancer Plasma EGFR Mutation Tests in the Clinical Setting.	0
77	Molecular Pathology of Lung Tumors. 2021 , 633-669	0
76	Circ_0091537 promotes gefitinib chemoresistance in non-small cell lung cancer by mediating the miR-520h/YAP1 network. Publish Ahead of Print,	0
75	FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC. 29,	0
74	Comprehensive Genomic Profiling in Lung Cancer in the Era of Immunotherapy Approaches: The Role of Molecular Tumour Boards. 2023 ,	0
73	Apoptosis signaling in EGFR inhibitor resistance in NSCLC. 2023 , 71-88	0
72	HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors. 13,	0
71	Liquid biopsy: new challenges in the era of immunotherapy and precision oncology NGS and the other faces of molecular biology. 2023 , 47-62	0
70	Synthesis, Molecular Dynamics Simulation, and In-vitro Antitumor Activity of Quinazoline-2,4,6-triamine Derivatives as Novel EGFR Tyrosine Kinase Inhibitors. 2023 , 21,	0

- 69 Historical development of EGFR-targeted therapy. **2023**, 1-11 ○
- 68 Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. **2023**, 13-27 ○
- 67 In Vitro Validation of Computationally Predicted Oncogenic Driver Mutations in EGFR Tyrosine Kinase Domain. ○
- 66 Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations. **2023**, 15, 175883592211461 ○
- 65 Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia. **2023**, ○
- 64 Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study. ○
- 63 Synthesis of novel amide/amino acid functionalized pyrazolo[3,4- b]pyridine derivatives; their anticancer activity and docking studies. ○
- 62 Effects of Ephedra Herb extract on the expression of EGFR-activating mutations and c-Met in non-small-cell lung cancer cell line, H1975, and its combined effects with osimertinib. ○
- 61 Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma. **2023**, 161, 114452 ○
- 60 Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer. ○
- 59 EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and meta-analysis. **2023**, 119, 110001 ○
- 58 Digital ECMT Cancer Trial Matching Tool: an Open Source Research Application to Support Oncologists in the Identification of Precision Medicine Clinical Trials. **2023**, ○
- 57 Imidazo[1,2-a]quinazolines as novel, potent EGFR-TK inhibitors: Design, synthesis, bioactivity evaluation, and in silico studies. **2023**, 133, 106383 ○
- 56 Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer. **2023**, 13, 210 ○
- 55 Molecular Testing for Diagnostics, Prognostication, and Treatment Stratification in Cancers. **2023**, 29, 3-8 ○
- 54 Molekulare Diagnostik und molekulares Tumorboard. **2022**, 359-376 ○
- 53 A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy. **2023**, 177, 44-50 ○
- 52 6-Shogaol Overcomes Gefitinib Resistance via ER Stress in Ovarian Cancer Cells. **2023**, 24, 2639 ○

- 51 Niclosamide nanocrystal for enhanced in-vivo efficacy against gastrointestinal stromal tumor via regulating EGFR/STAT-3/DR-4 axis. **2023**, 81, 104221 ○
- 50 Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations. **2023**, 11, 6 ○
- 49 The development and implementation of EGFR inhibitors in advanced NSCLC. **2023**, 13-36 ○
- 48 Liquid Biopsy for Oral Cancer Diagnosis: Recent Advances and Challenges. **2023**, 13, 303 ○
- 47 Structure optimization and discovery of novel compound for the treatment of insertion mutations within exon 20 of EGFR and HER2. **2023**, 81, 117202 ○
- 46 The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review. **2023**, 128, 316-329 ○
- 45 How cells sense and integrate information from different sources. ○
- 44 Trans-activating mutations of the pseudokinase ERBB3. ○
- 43 Anti-ROR1 CAR-T cells: Architecture and performance. 10, ○
- 42 Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC. **2023**, 24, 4126 ○
- 41 Efficient and accurate KRAS genotyping using digital PCR combined with melting curve analysis for ctDNA from pancreatic cancer patients. **2023**, 13, ○
- 40 A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma. ○
- 39 A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine. **2023**, 12, 1936 ○
- 38 Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide. ○
- 37 Evolution of cancer genomics and its clinical implications. **2019**, 9, 173-178 ○
- 36 Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy. **2023**, 23, ○
- 35 Comparison of Ultra-Magnifying Endocytoscopic and Hematoxylin-Eosin-Stained Images of Lung Specimens. **2023**, 13, 1003 ○
- 34 Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. **2023**, 13, ○

- 33 Intelligent Genetic Decoding System Based on Nucleic Acid Isothermal Amplification for Non-Small Cell Lung Cancer Diagnosis. **2023**, 14, 647 ○
- 32 Different treatment efficacies and T790M acquisition of EGFR-TKIs on NSCLC patients with variable Del-19 subtypes of EGFR . ○
- 31 Modulation of EGFR by Oral Squamous Cell Carcinoma Cell Lines. **2009**, 37, 869-874 ○
- 30 Tumor plasticity and therapeutic resistance in oncogene-addicted non-small cell lung cancer: from preclinical observations to clinical implications. **2023**, 184, 103966 ○
- 29 Triptolide reduces PD-L1 through the EGFR and IFN- γ /IRF1 dual signaling pathways. **2023**, 118, 109993 ○
- 28 Trends in Survival Rates of NonSmall Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020. **2023**, 6, e232002 ○
- 27 Synthesis and evaluation of sulfonamide derivatives targeting EGFR790M/L858R mutations and ALK rearrangement as anticancer agents. **2023**, 85, 117241 ○
- 26 Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. **2023**, 15, 175883592311614 ○
- 25 Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs. **2023**, 24, 5821 ○
- 24 Multi-omics analysis identifies drivers of protein phosphorylation. **2023**, 24, ○
- 23 CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma. **2023**, 23, ○
- 22 Onionin A inhibits small-cell lung cancer proliferation through suppressing STAT3 activation induced by macrophages-derived IL-6 and cell-cell interaction with tumor-associated macrophage. **2023**, 36, 1068-1080 ○
- 21 Molecular Pathology of Lung Cancer. ○
- 20 EBUS-TBNA of a Left Lower Paratracheal Node (Level 4' L) in a Patient with a Left Upper Lobe Lung Mass and Suspected Lung Cancer. **2012**, 207-218 ○
- 19 Comparison of long-term outcomes of stereotactic body radiotherapy (SBRT) via Helical tomotherapy for early-stage lung cancer with or without pathological proof. **2023**, 18, ○
- 18 Precision oncology comes of age. **2023**, 36, 28-31 ○
- 17 EGFR inhibition in lung adenocarcinoma upregulates cell surface expression of the placental antigen ALPP and enhances efficacy of ALPP-ADC therapy. ○
- 16 Mechanism exploration and prognosis study of Astragali Radix-Spreading hedyotis herb for the treatment of lung adenocarcinoma based on bioinformatics approaches and molecular dynamics simulation. 11, ○

- 15 Exosome-derived circKIF20B suppresses gefitinib resistance and cell proliferation in non-small cell lung cancer. ○
- 14 Tumor-specific activity of precision medicines in the NCI-MATCH trial. ○
- 13 Imaging Follow-Up of Nonsurgical Therapies for Lung Cancer: AJR Expert Panel Narrative Review. ○
- 12 Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice. 14, ○
- 11 Structure-based virtual screening and molecular dynamics simulations for detecting novel candidates for allosteric inhibition of EGFR T790M. 1-27 ○
- 10 Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment. ○
- 9 Personalizing therapy selection in inflammatory bowel disease. **2023**, 19, 431-438 ○
- 8 Accelerating the understanding of cancer biology through the lens of genomics. **2023**, 186, 1755-1771 ○
- 7 Investigation of Diagnostic and Prognostic Value of CLEC4M of Non-Small Cell Lung Carcinoma Associated with Immune Microenvironment. Volume 16, 1317-1332 ○
- 6 Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management. ○
- 5 A homologous and molecular dual-targeted biomimetic nanocarrier for EGFR-related non-small cell lung cancer therapy. **2023**, 27, 337-347 ○
- 4 Analytical Performance of a Highly Sensitive System to Detect Gene Variants Using Next-Generation Sequencing for Lung Cancer Companion Diagnostics. **2023**, 13, 1476 ○
- 3 Targeted therapy. **2023**, 205-411 ○
- 2 An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?. 13, ○
- 1 An association of epidermal growth factor receptor mutation subtypes with prognostic prediction and site-specific recurrence in advanced stage lung cancer patients. ○